JP2016532656A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016532656A5 JP2016532656A5 JP2016521333A JP2016521333A JP2016532656A5 JP 2016532656 A5 JP2016532656 A5 JP 2016532656A5 JP 2016521333 A JP2016521333 A JP 2016521333A JP 2016521333 A JP2016521333 A JP 2016521333A JP 2016532656 A5 JP2016532656 A5 JP 2016532656A5
- Authority
- JP
- Japan
- Prior art keywords
- chloro
- prop
- piperazin
- quinazolin
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 117
- -1 C 1 -C 6 alkoxy Chemical group 0.000 claims description 103
- 125000000217 alkyl group Chemical group 0.000 claims description 49
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 23
- 125000005843 halogen group Chemical group 0.000 claims description 23
- 125000001072 heteroaryl group Chemical group 0.000 claims description 21
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 21
- 125000000623 heterocyclic group Chemical group 0.000 claims description 18
- 125000001424 substituent group Chemical group 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 13
- 125000003118 aryl group Chemical group 0.000 claims description 12
- 229910052799 carbon Inorganic materials 0.000 claims description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 10
- 125000002837 carbocyclic group Chemical group 0.000 claims description 10
- 125000004966 cyanoalkyl group Chemical group 0.000 claims description 10
- 125000001153 fluoro group Chemical group F* 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 125000004181 carboxyalkyl group Chemical group 0.000 claims description 8
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 125000003545 alkoxy group Chemical group 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 125000002947 alkylene group Chemical group 0.000 claims description 3
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 2
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims description 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 2
- 125000004104 aryloxy group Chemical group 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000001246 bromo group Chemical group Br* 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 2
- 125000005433 dihydrobenzodioxinyl group Chemical group O1C(COC2=C1C=CC=C2)* 0.000 claims description 2
- 125000005044 dihydroquinolinyl group Chemical group N1(CC=CC2=CC=CC=C12)* 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000005114 heteroarylalkoxy group Chemical group 0.000 claims description 2
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 2
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims description 2
- 125000004468 heterocyclylthio group Chemical group 0.000 claims description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 125000004043 oxo group Chemical group O=* 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000011593 sulfur Substances 0.000 claims description 2
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 claims 65
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 33
- 125000004546 quinazolin-4-yl group Chemical group N1=CN=C(C2=CC=CC=C12)* 0.000 claims 26
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 9
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 5
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims 3
- YNMBXEWTXSZTHP-UHFFFAOYSA-N 1-[4-[6-chloro-7-(2-fluorophenyl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=CC=1C1=C(C=CC=C1)F)N1CCN(CC1)C(C=C)=O YNMBXEWTXSZTHP-UHFFFAOYSA-N 0.000 claims 2
- DCUNRLLJHAWKRZ-UHFFFAOYSA-N 5-methyl-1h-indazole Chemical compound CC1=CC=C2NN=CC2=C1 DCUNRLLJHAWKRZ-UHFFFAOYSA-N 0.000 claims 2
- ZRPZPNYZFSJUPA-UHFFFAOYSA-N ARS-1620 Chemical compound Oc1cccc(F)c1-c1c(Cl)cc2c(ncnc2c1F)N1CCN(CC1)C(=O)C=C ZRPZPNYZFSJUPA-UHFFFAOYSA-N 0.000 claims 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 2
- 125000004464 hydroxyphenyl group Chemical group 0.000 claims 2
- QZZYYBQGTSGDPP-UHFFFAOYSA-N quinoline-3-carbonitrile Chemical compound C1=CC=CC2=CC(C#N)=CN=C21 QZZYYBQGTSGDPP-UHFFFAOYSA-N 0.000 claims 2
- JIIBSIMXAXZDEL-INIZCTEOSA-N (2R)-4-[7-chloro-6-(4-chlorophenyl)quinazolin-4-yl]-1-prop-2-enoylpiperazine-2-carbonitrile Chemical compound C(C=C)(=O)N1[C@H](CN(CC1)C1=NC=NC2=CC(=C(C=C12)C1=CC=C(C=C1)Cl)Cl)C#N JIIBSIMXAXZDEL-INIZCTEOSA-N 0.000 claims 1
- JIIBSIMXAXZDEL-MRXNPFEDSA-N (2S)-4-[7-chloro-6-(4-chlorophenyl)quinazolin-4-yl]-1-prop-2-enoylpiperazine-2-carbonitrile Chemical compound Clc1ccc(cc1)-c1cc2c(ncnc2cc1Cl)N1CCN([C@@H](C1)C#N)C(=O)C=C JIIBSIMXAXZDEL-MRXNPFEDSA-N 0.000 claims 1
- FRSSAEVAURADPX-IBGZPJMESA-N (2S)-4-[7-chloro-6-(4-chlorophenyl)quinazolin-4-yl]-1-prop-2-enoylpiperazine-2-carboxamide Chemical compound NC(=O)[C@@H]1CN(CCN1C(=O)C=C)c1ncnc2cc(Cl)c(cc12)-c1ccc(Cl)cc1 FRSSAEVAURADPX-IBGZPJMESA-N 0.000 claims 1
- QKASFJNWWCTSGP-RMKNXTFCSA-N (E)-1-[4-(6-chloro-7-phenylquinazolin-4-yl)piperazin-1-yl]-4-(dimethylamino)but-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=CC=1C1=CC=CC=C1)N1CCN(CC1)C(\C=C\CN(C)C)=O QKASFJNWWCTSGP-RMKNXTFCSA-N 0.000 claims 1
- VGKOBAAKSQZNCD-VMPITWQZSA-N (E)-1-[4-[6-chloro-7-(2-fluorophenyl)quinazolin-4-yl]piperazin-1-yl]-4-(dimethylamino)but-2-en-1-one Chemical compound CN(C)C\C=C\C(=O)N1CCN(CC1)C1=NC=NC2=CC(=C(Cl)C=C12)C1=C(F)C=CC=C1 VGKOBAAKSQZNCD-VMPITWQZSA-N 0.000 claims 1
- REYPQWDSLONYOF-QPJJXVBHSA-N (E)-1-[4-[6-chloro-8-fluoro-7-(2-fluoro-6-hydroxyphenyl)quinazolin-4-yl]piperazin-1-yl]-4-(dimethylamino)but-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=C(C=1C1=C(C=CC=C1O)F)F)N1CCN(CC1)C(\C=C\CN(C)C)=O REYPQWDSLONYOF-QPJJXVBHSA-N 0.000 claims 1
- LPYMUYXNZNCYEE-VMPITWQZSA-N (E)-1-[4-[6-chloro-8-fluoro-7-(2-fluorophenyl)quinazolin-4-yl]piperazin-1-yl]-4-(dimethylamino)but-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=C(C=1C1=C(C=CC=C1)F)F)N1CCN(CC1)C(\C=C\CN(C)C)=O LPYMUYXNZNCYEE-VMPITWQZSA-N 0.000 claims 1
- DQBWLZZZBFAZMQ-VMPITWQZSA-N (E)-1-[4-[6-chloro-8-fluoro-7-(3-hydroxynaphthalen-1-yl)quinazolin-4-yl]piperazin-1-yl]-4-(dimethylamino)but-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=C(C=1C1=CC(=CC2=CC=CC=C12)O)F)N1CCN(CC1)C(\C=C\CN(C)C)=O DQBWLZZZBFAZMQ-VMPITWQZSA-N 0.000 claims 1
- IMOLPJTUMWEJAN-NSCUHMNNSA-N (E)-1-[4-[6-chloro-8-fluoro-7-(5-methyl-1H-indazol-4-yl)quinazolin-4-yl]piperazin-1-yl]-4-hydroxybut-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=C(C=1C1=C2C=NNC2=CC=C1C)F)N1CCN(CC1)C(\C=C\CO)=O IMOLPJTUMWEJAN-NSCUHMNNSA-N 0.000 claims 1
- NIGLWQWHTJDRJH-VMPITWQZSA-N (E)-1-[4-[7-chloro-6-(2-chlorophenyl)quinazolin-4-yl]piperazin-1-yl]-4-(dimethylamino)but-2-en-1-one Chemical compound ClC1=C(C=C2C(=NC=NC2=C1)N1CCN(CC1)C(\C=C\CN(C)C)=O)C1=C(C=CC=C1)Cl NIGLWQWHTJDRJH-VMPITWQZSA-N 0.000 claims 1
- RZPUJQSVHYOXNU-GZTJUZNOSA-N (E)-2-[4-[6-chloro-7-(2-fluorophenyl)quinazolin-4-yl]piperazine-1-carbonyl]-4-methylpent-2-enenitrile Chemical compound ClC=1C=C2C(=NC=NC2=CC=1C1=C(C=CC=C1)F)N1CCN(CC1)C(=O)\C(\C#N)=C\C(C)C RZPUJQSVHYOXNU-GZTJUZNOSA-N 0.000 claims 1
- ACCCQSRYERZRNL-GHRIWEEISA-N (E)-2-[4-[6-chloro-7-(2-fluorophenyl)quinazolin-4-yl]piperazine-1-carbonyl]-5-hydroxy-4,4-dimethylpent-2-enenitrile Chemical compound ClC=1C=C2C(=NC=NC2=CC=1C1=C(C=CC=C1)F)N1CCN(CC1)C(=O)\C(\C#N)=C\C(CO)(C)C ACCCQSRYERZRNL-GHRIWEEISA-N 0.000 claims 1
- KQDAQPDKNQDMST-RIYZIHGNSA-N (E)-2-[4-[6-chloro-8-fluoro-7-(2-fluoro-6-hydroxyphenyl)quinazolin-4-yl]piperazine-1-carbonyl]-3-(1,3-thiazol-5-yl)prop-2-enenitrile Chemical compound ClC=1C=C2C(=NC=NC2=C(C=1C1=C(C=CC=C1O)F)F)N1CCN(CC1)C(=O)\C(\C#N)=C\C1=CN=CS1 KQDAQPDKNQDMST-RIYZIHGNSA-N 0.000 claims 1
- HDHVYWZGKMVUEE-FOWTUZBSSA-N (E)-2-[4-[6-chloro-8-fluoro-7-(2-fluoro-6-hydroxyphenyl)quinazolin-4-yl]piperazine-1-carbonyl]-3-pyridin-2-ylprop-2-enenitrile Chemical compound ClC=1C=C2C(=NC=NC2=C(C=1C1=C(C=CC=C1O)F)F)N1CCN(CC1)C(=O)\C(\C#N)=C\C1=NC=CC=C1 HDHVYWZGKMVUEE-FOWTUZBSSA-N 0.000 claims 1
- FZIMVEXNZMVGNL-XNTDXEJSSA-N (E)-2-[4-[6-chloro-8-fluoro-7-(2-fluoro-6-hydroxyphenyl)quinazolin-4-yl]piperazine-1-carbonyl]-4-methylpent-2-enenitrile Chemical compound ClC=1C=C2C(=NC=NC2=C(C=1C1=C(C=CC=C1O)F)F)N1CCN(CC1)C(=O)\C(\C#N)=C\C(C)C FZIMVEXNZMVGNL-XNTDXEJSSA-N 0.000 claims 1
- VDTBGHRLBSOPJH-KPKJPENVSA-N (E)-4-(dimethylamino)-1-[4-[8-fluoro-6,7-bis(2-fluorophenyl)quinazolin-4-yl]piperazin-1-yl]but-2-en-1-one Chemical compound CN(C/C=C/C(=O)N1CCN(CC1)C1=NC=NC2=C(C(=C(C=C12)C1=C(C=CC=C1)F)C1=C(C=CC=C1)F)F)C VDTBGHRLBSOPJH-KPKJPENVSA-N 0.000 claims 1
- ZOKDLNHHGMBAMY-NSCUHMNNSA-N (E)-4-amino-1-[4-[6-chloro-8-fluoro-7-(5-methyl-1H-indazol-4-yl)quinazolin-4-yl]piperazin-1-yl]but-2-en-1-one Chemical compound NC/C=C/C(=O)N1CCN(CC1)C1=NC=NC2=C(C(=C(C=C12)Cl)C1=C2C=NNC2=CC=C1C)F ZOKDLNHHGMBAMY-NSCUHMNNSA-N 0.000 claims 1
- SVWRZGYZVNEDSK-UPHRSURJSA-N (Z)-4-[4-[6-chloro-7-(2,4-difluorophenyl)quinazolin-4-yl]piperazin-1-yl]-4-oxobut-2-enenitrile Chemical compound FC1=CC(F)=C(C=C1)C1=C(Cl)C=C2C(=C1)N=CN=C2N1CCN(CC1)C(=O)\C=C/C#N SVWRZGYZVNEDSK-UPHRSURJSA-N 0.000 claims 1
- IFKLZUNLNWQOAI-MRXNPFEDSA-N 1-[(2R)-4-[7-chloro-6-(4-chlorophenyl)quinazolin-4-yl]-2-(hydroxymethyl)piperazin-1-yl]prop-2-en-1-one Chemical compound ClC1=C(C=C2C(=NC=NC2=C1)N1C[C@@H](N(CC1)C(C=C)=O)CO)C1=CC=C(C=C1)Cl IFKLZUNLNWQOAI-MRXNPFEDSA-N 0.000 claims 1
- IFKLZUNLNWQOAI-INIZCTEOSA-N 1-[(2S)-4-[7-chloro-6-(4-chlorophenyl)quinazolin-4-yl]-2-(hydroxymethyl)piperazin-1-yl]prop-2-en-1-one Chemical compound OC[C@@H]1CN(CCN1C(=O)C=C)c1ncnc2cc(Cl)c(cc12)-c1ccc(Cl)cc1 IFKLZUNLNWQOAI-INIZCTEOSA-N 0.000 claims 1
- JONQXARUZMFDMA-UHFFFAOYSA-N 1-[2-[6-chloro-4-(4-prop-2-enoylpiperazin-1-yl)quinazolin-7-yl]phenyl]cyclopropane-1-carbonitrile Chemical compound C(C=C)(=O)N1CCN(CC1)C1=NC=NC2=CC(=C(C=C12)Cl)C1=C(C=CC=C1)C1(CC1)C#N JONQXARUZMFDMA-UHFFFAOYSA-N 0.000 claims 1
- AGSDVWSMKBITHV-UHFFFAOYSA-N 1-[3-[6-chloro-4-(4-prop-2-enoylpiperazin-1-yl)quinazolin-7-yl]-4-fluorophenyl]cyclopropane-1-carbonitrile Chemical compound C(C=C)(=O)N1CCN(CC1)C1=NC=NC2=CC(=C(C=C12)Cl)C=1C=C(C=CC=1F)C1(CC1)C#N AGSDVWSMKBITHV-UHFFFAOYSA-N 0.000 claims 1
- OAKNVDIGUBBNCK-UHFFFAOYSA-N 1-[4-(6-chloro-2-methoxy-7-phenylquinazolin-4-yl)piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC(=NC2=CC=1C1=CC=CC=C1)OC)N1CCN(CC1)C(C=C)=O OAKNVDIGUBBNCK-UHFFFAOYSA-N 0.000 claims 1
- CEFRQJDZWPCQQP-UHFFFAOYSA-N 1-[4-(6-chloro-2-methyl-7-phenylquinazolin-4-yl)piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC(=NC2=CC=1C1=CC=CC=C1)C)N1CCN(CC1)C(C=C)=O CEFRQJDZWPCQQP-UHFFFAOYSA-N 0.000 claims 1
- QSLWYNJTXZGWSB-UHFFFAOYSA-N 1-[4-(6-chloro-7-naphthalen-1-ylquinazolin-4-yl)piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=CC=1C1=CC=CC2=CC=CC=C12)N1CCN(CC1)C(C=C)=O QSLWYNJTXZGWSB-UHFFFAOYSA-N 0.000 claims 1
- REXOZNLXIGVHSQ-UHFFFAOYSA-N 1-[4-(6-chloro-7-phenylquinolin-4-yl)piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=CC=NC2=CC=1C1=CC=CC=C1)N1CCN(CC1)C(C=C)=O REXOZNLXIGVHSQ-UHFFFAOYSA-N 0.000 claims 1
- LBKJYIJVHAUCQZ-UHFFFAOYSA-N 1-[4-(6-chloro-7-piperidin-1-ylquinazolin-4-yl)piperazin-1-yl]prop-2-en-1-one Chemical compound ClC1=C(C=C2N=CN=C(N3CCN(CC3)C(=O)C=C)C2=C1)N1CCCCC1 LBKJYIJVHAUCQZ-UHFFFAOYSA-N 0.000 claims 1
- MKJFJWZQRYDKCL-UHFFFAOYSA-N 1-[4-(6-chloro-7-pyridin-2-ylquinazolin-4-yl)piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=CC=1C1=NC=CC=C1)N1CCN(CC1)C(C=C)=O MKJFJWZQRYDKCL-UHFFFAOYSA-N 0.000 claims 1
- LNYQRNIFKHWDBC-UHFFFAOYSA-N 1-[4-(6-chloro-7-pyridin-3-ylquinazolin-4-yl)piperazin-1-yl]prop-2-en-1-one Chemical compound ClC1=C(C=C2N=CN=C(N3CCN(CC3)C(=O)C=C)C2=C1)C1=CN=CC=C1 LNYQRNIFKHWDBC-UHFFFAOYSA-N 0.000 claims 1
- WQFZLGPSWWBEQU-UHFFFAOYSA-N 1-[4-(6-chloro-7-quinazolin-8-ylquinazolin-4-yl)piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=CC1C=1C=CC=C2C=NC=NC12)N1CCN(CC1)C(C=C)=O WQFZLGPSWWBEQU-UHFFFAOYSA-N 0.000 claims 1
- QUTHCVSAOWLVEI-UHFFFAOYSA-N 1-[4-(6-chloro-7-quinolin-4-ylquinazolin-4-yl)piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=CC=1C1=CC=NC2=CC=CC=C12)N1CCN(CC1)C(C=C)=O QUTHCVSAOWLVEI-UHFFFAOYSA-N 0.000 claims 1
- PCOOMHAOSSAFSA-UHFFFAOYSA-N 1-[4-(6-chloro-7-quinolin-5-ylquinazolin-4-yl)piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=CC=1C1=C2C=CC=NC2=CC=C1)N1CCN(CC1)C(C=C)=O PCOOMHAOSSAFSA-UHFFFAOYSA-N 0.000 claims 1
- GOMAQQZCOVNYNI-UHFFFAOYSA-N 1-[4-(6-chloro-7-thiophen-2-ylquinazolin-4-yl)piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=CC=1C=1SC=CC=1)N1CCN(CC1)C(C=C)=O GOMAQQZCOVNYNI-UHFFFAOYSA-N 0.000 claims 1
- QWISGKNZGQOAJG-UHFFFAOYSA-N 1-[4-(6-ethyl-7-phenylquinazolin-4-yl)piperazin-1-yl]prop-2-en-1-one Chemical compound C(C)C=1C=C2C(=NC=NC2=CC=1C1=CC=CC=C1)N1CCN(CC1)C(C=C)=O QWISGKNZGQOAJG-UHFFFAOYSA-N 0.000 claims 1
- QCNFSVAJKRKWFW-UHFFFAOYSA-N 1-[4-(7-chloro-6-morpholin-4-ylquinazolin-4-yl)piperazin-1-yl]prop-2-en-1-one Chemical compound ClC1=C(C=C2C(=NC=NC2=C1)N1CCN(CC1)C(C=C)=O)N1CCOCC1 QCNFSVAJKRKWFW-UHFFFAOYSA-N 0.000 claims 1
- JFWXDEIZSVTXMO-UHFFFAOYSA-N 1-[4-(7-chloro-6-phenylisoquinolin-1-yl)piperazin-1-yl]prop-2-en-1-one Chemical compound ClC1=C(C=C2C=CN=C(C2=C1)N1CCN(CC1)C(C=C)=O)C1=CC=CC=C1 JFWXDEIZSVTXMO-UHFFFAOYSA-N 0.000 claims 1
- ZPPGBGCDKOFVIA-UHFFFAOYSA-N 1-[4-(7-chloro-6-phenylquinazolin-4-yl)piperazin-1-yl]prop-2-en-1-one Chemical compound Clc1cc2ncnc(N3CCN(CC3)C(=O)C=C)c2cc1-c1ccccc1 ZPPGBGCDKOFVIA-UHFFFAOYSA-N 0.000 claims 1
- UJHGFLSPKCXWDS-UHFFFAOYSA-N 1-[4-(7-chloro-6-pyridin-3-ylquinazolin-4-yl)piperazin-1-yl]prop-2-en-1-one Chemical compound ClC1=C(C=C2C(=NC=NC2=C1)N1CCN(CC1)C(C=C)=O)C=1C=NC=CC=1 UJHGFLSPKCXWDS-UHFFFAOYSA-N 0.000 claims 1
- YQAQQFKSOLAQFT-UHFFFAOYSA-N 1-[4-(7-chloro-6-pyridin-4-ylquinazolin-4-yl)piperazin-1-yl]prop-2-en-1-one Chemical compound ClC1=C(C=C2C(=C1)N=CN=C2N1CCN(CC1)C(=O)C=C)C1=CC=NC=C1 YQAQQFKSOLAQFT-UHFFFAOYSA-N 0.000 claims 1
- VDZZZNHNNCUOMP-UHFFFAOYSA-N 1-[4-(7-chloro-6-thiophen-2-ylquinazolin-4-yl)piperazin-1-yl]prop-2-en-1-one Chemical compound ClC1=C(C=C2C(=NC=NC2=C1)N1CCN(CC1)C(C=C)=O)C=1SC=CC=1 VDZZZNHNNCUOMP-UHFFFAOYSA-N 0.000 claims 1
- USWJXUMSFMWEPQ-UHFFFAOYSA-N 1-[4-[2-amino-7-chloro-6-(4-chlorophenyl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound Nc1nc(N2CCN(CC2)C(=O)C=C)c2cc(c(Cl)cc2n1)-c1ccc(Cl)cc1 USWJXUMSFMWEPQ-UHFFFAOYSA-N 0.000 claims 1
- LCQKRNAPYQFDFW-UHFFFAOYSA-N 1-[4-[5-(2-chlorophenyl)-4a,7a-dihydrothieno[2,3-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC1=C(C=CC=C1)C1=CSC2N=CN=C(C21)N1CCN(CC1)C(C=C)=O LCQKRNAPYQFDFW-UHFFFAOYSA-N 0.000 claims 1
- UKBLZUDQPGVFEN-UHFFFAOYSA-N 1-[4-[5-(2-chlorophenyl)-7,7a-dihydro-4aH-pyrrolo[2,3-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC1=C(C=CC=C1)C1=CNC2N=CN=C(C21)N1CCN(CC1)C(C=C)=O UKBLZUDQPGVFEN-UHFFFAOYSA-N 0.000 claims 1
- YAOXGOQNIDBBIA-UHFFFAOYSA-N 1-[4-[6,8-dichloro-7-(2-methoxynaphthalen-1-yl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=C(C=1C1=C(C=CC2=CC=CC=C12)OC)Cl)N1CCN(CC1)C(C=C)=O YAOXGOQNIDBBIA-UHFFFAOYSA-N 0.000 claims 1
- YDUYZFMHUOIQCH-UHFFFAOYSA-N 1-[4-[6-(2-chlorophenyl)-7-fluoroquinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC1=C(C=CC=C1)C=1C=C2C(=NC=NC2=CC=1F)N1CCN(CC1)C(C=C)=O YDUYZFMHUOIQCH-UHFFFAOYSA-N 0.000 claims 1
- KBPOZSHJOYBGJO-UHFFFAOYSA-N 1-[4-[6-(4-bromophenyl)-7-chloroquinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound BrC1=CC=C(C=C1)C=1C=C2C(=NC=NC2=CC=1Cl)N1CCN(CC1)C(C=C)=O KBPOZSHJOYBGJO-UHFFFAOYSA-N 0.000 claims 1
- PVVYUDCPISEZPW-UHFFFAOYSA-N 1-[4-[6-(4-chlorophenyl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC1=CC=C(C=C1)C=1C=C2C(=NC=NC2=CC=1)N1CCN(CC1)C(C=C)=O PVVYUDCPISEZPW-UHFFFAOYSA-N 0.000 claims 1
- NIKZHNQHYNRRTH-UHFFFAOYSA-N 1-[4-[6-(trifluoromethyl)-7-[2-(trifluoromethyl)phenyl]quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound FC(C=1C=C2C(=NC=NC2=CC=1C1=C(C=CC=C1)C(F)(F)F)N1CCN(CC1)C(C=C)=O)(F)F NIKZHNQHYNRRTH-UHFFFAOYSA-N 0.000 claims 1
- FIVMEWZHXYVFSM-UHFFFAOYSA-N 1-[4-[6-chloro-2-(methylamino)-7-(5-methyl-1H-indazol-4-yl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC(=NC2=CC=1C1=C2C=NNC2=CC=C1C)NC)N1CCN(CC1)C(C=C)=O FIVMEWZHXYVFSM-UHFFFAOYSA-N 0.000 claims 1
- HTYWTFMIOROXAZ-UHFFFAOYSA-N 1-[4-[6-chloro-2-[2-(dimethylamino)ethoxy]-8-fluoro-7-(2-fluoro-6-hydroxyphenyl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC(=NC2=C(C=1C1=C(C=CC=C1O)F)F)OCCN(C)C)N1CCN(CC1)C(C=C)=O HTYWTFMIOROXAZ-UHFFFAOYSA-N 0.000 claims 1
- YGBHSZUSILDDFX-UHFFFAOYSA-N 1-[4-[6-chloro-2-[2-(dimethylamino)ethoxy]-8-fluoro-7-(3-hydroxynaphthalen-1-yl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC(=NC2=C(C=1C1=CC(=CC2=CC=CC=C12)O)F)OCCN(C)C)N1CCN(CC1)C(C=C)=O YGBHSZUSILDDFX-UHFFFAOYSA-N 0.000 claims 1
- QDBNFRCUYRSZRX-UHFFFAOYSA-N 1-[4-[6-chloro-2-[2-(dimethylamino)ethyl-methylamino]-8-fluoro-7-(3-hydroxynaphthalen-1-yl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC(=NC2=C(C=1C1=CC(=CC2=CC=CC=C12)O)F)N(C)CCN(C)C)N1CCN(CC1)C(C=C)=O QDBNFRCUYRSZRX-UHFFFAOYSA-N 0.000 claims 1
- LEZSBJPQYYYXLL-UHFFFAOYSA-N 1-[4-[6-chloro-2-[2-(dimethylamino)ethyl-methylamino]-8-fluoro-7-(5-methyl-1H-indazol-4-yl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC(=NC2=C(C=1C1=C2C=NNC2=CC=C1C)F)N(C)CCN(C)C)N1CCN(CC1)C(C=C)=O LEZSBJPQYYYXLL-UHFFFAOYSA-N 0.000 claims 1
- JOJJUMPADFNQKT-UHFFFAOYSA-N 1-[4-[6-chloro-2-[3-(dimethylamino)propoxy]-7-(5-methyl-1H-indazol-4-yl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC(=NC2=CC=1C1=C2C=NNC2=CC=C1C)OCCCN(C)C)N1CCN(CC1)C(C=C)=O JOJJUMPADFNQKT-UHFFFAOYSA-N 0.000 claims 1
- YGAKEXBYIBLQJP-UHFFFAOYSA-N 1-[4-[6-chloro-2-[3-(dimethylamino)propoxy]-8-fluoro-7-(5-methyl-1H-indazol-4-yl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC(=NC2=C(C=1C1=C2C=NNC2=CC=C1C)F)OCCCN(C)C)N1CCN(CC1)C(C=C)=O YGAKEXBYIBLQJP-UHFFFAOYSA-N 0.000 claims 1
- QNDAMYVBIWPDCM-UHFFFAOYSA-N 1-[4-[6-chloro-3-ethynyl-7-(2-fluorophenyl)quinolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound FC1=C(C=CC=C1)C1=C(Cl)C=C2C(=C1)N=CC(C#C)=C2N1CCN(CC1)C(=O)C=C QNDAMYVBIWPDCM-UHFFFAOYSA-N 0.000 claims 1
- NKTUSZJFMROTTG-UHFFFAOYSA-N 1-[4-[6-chloro-5-(2-chlorophenyl)-1H-indazol-3-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC1=C(C=C2C(=NNC2=C1)N1CCN(CC1)C(C=C)=O)C1=C(C=CC=C1)Cl NKTUSZJFMROTTG-UHFFFAOYSA-N 0.000 claims 1
- PRQGKPXTVNFULA-UHFFFAOYSA-N 1-[4-[6-chloro-5-fluoro-7-(2-fluoro-6-hydroxyphenyl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound Oc1cccc(F)c1-c1cc2ncnc(N3CCN(CC3)C(=O)C=C)c2c(F)c1Cl PRQGKPXTVNFULA-UHFFFAOYSA-N 0.000 claims 1
- DTOGBQCJAPEFTN-UHFFFAOYSA-N 1-[4-[6-chloro-7-(1,2,3,4-tetrahydroquinolin-5-yl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=CC=1C1=C2CCCNC2=CC=C1)N1CCN(CC1)C(C=C)=O DTOGBQCJAPEFTN-UHFFFAOYSA-N 0.000 claims 1
- VHBQYQDQURWJRD-UHFFFAOYSA-N 1-[4-[6-chloro-7-(1-methylindazol-3-yl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=CC=1C1=NN(C2=CC=CC=C12)C)N1CCN(CC1)C(C=C)=O VHBQYQDQURWJRD-UHFFFAOYSA-N 0.000 claims 1
- FTNPFWBZTIRYTO-UHFFFAOYSA-N 1-[4-[6-chloro-7-(1H-indazol-5-yl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=CC=1C=1C=C2C=NNC2=CC=1)N1CCN(CC1)C(C=C)=O FTNPFWBZTIRYTO-UHFFFAOYSA-N 0.000 claims 1
- KZOKCMMDKLSEML-UHFFFAOYSA-N 1-[4-[6-chloro-7-(1H-indazol-7-yl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=CC=1C=1C=CC=C2C=NNC=12)N1CCN(CC1)C(C=C)=O KZOKCMMDKLSEML-UHFFFAOYSA-N 0.000 claims 1
- XSTXHFFXTAFSNX-UHFFFAOYSA-N 1-[4-[6-chloro-7-(2,3-dihydro-1,4-benzodioxin-5-yl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC1=C(C=C2N=CN=C(N3CCN(CC3)C(=O)C=C)C2=C1)C1=CC=CC2=C1OCCO2 XSTXHFFXTAFSNX-UHFFFAOYSA-N 0.000 claims 1
- GDOJQXONAXYAHV-UHFFFAOYSA-N 1-[4-[6-chloro-7-(2,4-dichlorophenyl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=CC=1C1=C(C=C(C=C1)Cl)Cl)N1CCN(CC1)C(C=C)=O GDOJQXONAXYAHV-UHFFFAOYSA-N 0.000 claims 1
- SAQFOJAOJBQOHA-UHFFFAOYSA-N 1-[4-[6-chloro-7-(2,4-difluoro-5-hydroxyphenyl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=CC=1C1=C(C=C(C(=C1)O)F)F)N1CCN(CC1)C(C=C)=O SAQFOJAOJBQOHA-UHFFFAOYSA-N 0.000 claims 1
- NOHXGDXXLQUYNN-UHFFFAOYSA-N 1-[4-[6-chloro-7-(2,4-difluorophenyl)-8-fluoroquinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=C(C=1C1=C(C=C(C=C1)F)F)F)N1CCN(CC1)C(C=C)=O NOHXGDXXLQUYNN-UHFFFAOYSA-N 0.000 claims 1
- ZQCRLVOLDJTCNL-UHFFFAOYSA-N 1-[4-[6-chloro-7-(2,4-difluorophenyl)-8-hydroxyquinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound Oc1c(c(Cl)cc2c(ncnc12)N1CCN(CC1)C(=O)C=C)-c1ccc(F)cc1F ZQCRLVOLDJTCNL-UHFFFAOYSA-N 0.000 claims 1
- TWYZWUWWASKLHM-UHFFFAOYSA-N 1-[4-[6-chloro-7-(2,4-difluorophenyl)cinnolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=CN=NC2=CC=1C1=C(C=C(C=C1)F)F)N1CCN(CC1)C(C=C)=O TWYZWUWWASKLHM-UHFFFAOYSA-N 0.000 claims 1
- LYESZICKUICZAC-UHFFFAOYSA-N 1-[4-[6-chloro-7-(2,4-difluorophenyl)quinazolin-4-yl]-2-ethynylpiperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=CC=1C1=C(C=C(C=C1)F)F)N1CC(N(CC1)C(C=C)=O)C#C LYESZICKUICZAC-UHFFFAOYSA-N 0.000 claims 1
- UPGQAEWXYBUNCX-UHFFFAOYSA-N 1-[4-[6-chloro-7-(2,4-difluorophenyl)quinazolin-4-yl]piperazin-1-yl]-4-hydroxybut-2-yn-1-one Chemical compound OCC#CC(=O)N1CCN(CC1)C1=NC=NC2=CC(=C(Cl)C=C12)C1=C(F)C=C(F)C=C1 UPGQAEWXYBUNCX-UHFFFAOYSA-N 0.000 claims 1
- JJDGZJUMIJUXLS-UHFFFAOYSA-N 1-[4-[6-chloro-7-(2,4-difluorophenyl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=CC=1C1=C(C=C(C=C1)F)F)N1CCN(CC1)C(C=C)=O JJDGZJUMIJUXLS-UHFFFAOYSA-N 0.000 claims 1
- QRGJYDRMVSXRKT-UHFFFAOYSA-N 1-[4-[6-chloro-7-(2,5-dichlorophenyl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=CC=1C1=C(C=CC(=C1)Cl)Cl)N1CCN(CC1)C(C=C)=O QRGJYDRMVSXRKT-UHFFFAOYSA-N 0.000 claims 1
- DPWYQQARBFEKJI-UHFFFAOYSA-N 1-[4-[6-chloro-7-(2,5-difluorophenyl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=CC=1C1=C(C=CC(=C1)F)F)N1CCN(CC1)C(C=C)=O DPWYQQARBFEKJI-UHFFFAOYSA-N 0.000 claims 1
- OLHVYQAUBZBXBI-UHFFFAOYSA-N 1-[4-[6-chloro-7-(2,6-difluorophenyl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=CC=1C1=C(C=CC=C1F)F)N1CCN(CC1)C(C=C)=O OLHVYQAUBZBXBI-UHFFFAOYSA-N 0.000 claims 1
- MAXRNAGCBBEQSE-UHFFFAOYSA-N 1-[4-[6-chloro-7-(2-chloro-6-methylphenyl)-8-fluoroquinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=C(C=1C1=C(C=CC=C1C)Cl)F)N1CCN(CC1)C(C=C)=O MAXRNAGCBBEQSE-UHFFFAOYSA-N 0.000 claims 1
- MTCHPZKBNNXDSP-UHFFFAOYSA-N 1-[4-[6-chloro-7-(2-chlorophenyl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=CC=1C1=C(C=CC=C1)Cl)N1CCN(CC1)C(C=C)=O MTCHPZKBNNXDSP-UHFFFAOYSA-N 0.000 claims 1
- CGGBNQSAHGYEEW-UHFFFAOYSA-N 1-[4-[6-chloro-7-(2-cyclopropylphenyl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=CC=1C1=C(C=CC=C1)C1CC1)N1CCN(CC1)C(C=C)=O CGGBNQSAHGYEEW-UHFFFAOYSA-N 0.000 claims 1
- MJRWXBIMCOZNDG-UHFFFAOYSA-N 1-[4-[6-chloro-7-(2-ethynylphenyl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=CC=1C1=C(C=CC=C1)C#C)N1CCN(CC1)C(C=C)=O MJRWXBIMCOZNDG-UHFFFAOYSA-N 0.000 claims 1
- QSAFZMROROICDI-UHFFFAOYSA-N 1-[4-[6-chloro-7-(2-fluoro-6-hydroxyphenyl)-8-methoxyquinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=C(C=1C1=C(C=CC=C1O)F)OC)N1CCN(CC1)C(C=C)=O QSAFZMROROICDI-UHFFFAOYSA-N 0.000 claims 1
- XJNKYVOSKDTGNY-UHFFFAOYSA-N 1-[4-[6-chloro-7-(2-fluoro-6-hydroxyphenyl)cinnolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound OC1=CC=CC(F)=C1C1=C(Cl)C=C2C(=C1)N=NC=C2N1CCN(CC1)C(=O)C=C XJNKYVOSKDTGNY-UHFFFAOYSA-N 0.000 claims 1
- PNYUIQVHHOUMPY-UHFFFAOYSA-N 1-[4-[6-chloro-7-(2-fluoro-6-hydroxyphenyl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=CC=1C1=C(C=CC=C1O)F)N1CCN(CC1)C(C=C)=O PNYUIQVHHOUMPY-UHFFFAOYSA-N 0.000 claims 1
- RDLWXWUVTLPGBV-UHFFFAOYSA-N 1-[4-[6-chloro-7-(2-fluoro-6-methoxyphenyl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=CC=1C1=C(C=CC=C1OC)F)N1CCN(CC1)C(C=C)=O RDLWXWUVTLPGBV-UHFFFAOYSA-N 0.000 claims 1
- PPRMFFNQNYSASM-UHFFFAOYSA-N 1-[4-[6-chloro-7-(2-fluorophenyl)cinnolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=CN=NC2=CC=1C1=C(C=CC=C1)F)N1CCN(CC1)C(C=C)=O PPRMFFNQNYSASM-UHFFFAOYSA-N 0.000 claims 1
- NUBHUDUXMHBKFO-UHFFFAOYSA-N 1-[4-[6-chloro-7-(2-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=CC=1C1=C(C=CC=2CCCCC1=2)O)N1CCN(CC1)C(C=C)=O NUBHUDUXMHBKFO-UHFFFAOYSA-N 0.000 claims 1
- AJCKDTGGCTYFTR-UHFFFAOYSA-N 1-[4-[6-chloro-7-(2-hydroxynaphthalen-1-yl)cinnolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=CN=NC2=CC=1C1=C(C=CC2=CC=CC=C12)O)N1CCN(CC1)C(C=C)=O AJCKDTGGCTYFTR-UHFFFAOYSA-N 0.000 claims 1
- KLCPIJNAJOAJJK-UHFFFAOYSA-N 1-[4-[6-chloro-7-(2-hydroxyphenyl)quinazolin-4-yl]-2-methylpiperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=CC=1C1=C(C=CC=C1)O)N1CC(N(CC1)C(C=C)=O)C KLCPIJNAJOAJJK-UHFFFAOYSA-N 0.000 claims 1
- XUYKRGJKJJLHSO-UHFFFAOYSA-N 1-[4-[6-chloro-7-(2-methoxynaphthalen-1-yl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=CC=1C1=C(C=CC2=CC=CC=C12)OC)N1CCN(CC1)C(C=C)=O XUYKRGJKJJLHSO-UHFFFAOYSA-N 0.000 claims 1
- CMDAVGAYVSXPPI-UHFFFAOYSA-N 1-[4-[6-chloro-7-(3,6-difluoro-2-hydroxyphenyl)-8-fluoroquinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound OC1=C(C(F)=CC=C1F)C1=C(Cl)C=C2C(=NC=NC2=C1F)N1CCN(CC1)C(=O)C=C CMDAVGAYVSXPPI-UHFFFAOYSA-N 0.000 claims 1
- LRSBGKBLVWYZAU-UHFFFAOYSA-N 1-[4-[6-chloro-7-(3-chlorophenyl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=CC=1C1=CC(=CC=C1)Cl)N1CCN(CC1)C(C=C)=O LRSBGKBLVWYZAU-UHFFFAOYSA-N 0.000 claims 1
- YWIAFWQZQRDGCZ-UHFFFAOYSA-N 1-[4-[6-chloro-7-(3-fluorophenyl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=CC=1C1=CC(=CC=C1)F)N1CCN(CC1)C(C=C)=O YWIAFWQZQRDGCZ-UHFFFAOYSA-N 0.000 claims 1
- NANCENFEOSVPDN-UHFFFAOYSA-N 1-[4-[6-chloro-7-(3-hydroxynaphthalen-1-yl)-8-methoxyquinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=C(C=1C1=CC(=CC2=CC=CC=C12)O)OC)N1CCN(CC1)C(C=C)=O NANCENFEOSVPDN-UHFFFAOYSA-N 0.000 claims 1
- JRYNAXYXBIOLTP-UHFFFAOYSA-N 1-[4-[6-chloro-7-(3-hydroxynaphthalen-1-yl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=CC=1C1=CC(=CC2=CC=CC=C12)O)N1CCN(CC1)C(C=C)=O JRYNAXYXBIOLTP-UHFFFAOYSA-N 0.000 claims 1
- GNILIFWTNWRJQE-UHFFFAOYSA-N 1-[4-[6-chloro-7-(3-hydroxyphenyl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=CC=1C1=CC(=CC=C1)O)N1CCN(CC1)C(C=C)=O GNILIFWTNWRJQE-UHFFFAOYSA-N 0.000 claims 1
- OBDYEUMTPLGJJO-UHFFFAOYSA-N 1-[4-[6-chloro-7-(3-methoxynaphthalen-1-yl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=CC=1C1=CC(=CC2=CC=CC=C12)OC)N1CCN(CC1)C(C=C)=O OBDYEUMTPLGJJO-UHFFFAOYSA-N 0.000 claims 1
- OVWRNKUEWKZFEE-UHFFFAOYSA-N 1-[4-[6-chloro-7-(4-chloro-2-fluorophenyl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=CC=1C1=C(C=C(C=C1)Cl)F)N1CCN(CC1)C(C=C)=O OVWRNKUEWKZFEE-UHFFFAOYSA-N 0.000 claims 1
- HOEOWSJVDZYHRF-UHFFFAOYSA-N 1-[4-[6-chloro-7-(4-chloro-2-hydroxyphenyl)isoquinolin-1-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound OC1=C(C=CC(Cl)=C1)C1=C(Cl)C=C2C=CN=C(N3CCN(CC3)C(=O)C=C)C2=C1 HOEOWSJVDZYHRF-UHFFFAOYSA-N 0.000 claims 1
- FXRQIENUNKJYLX-UHFFFAOYSA-N 1-[4-[6-chloro-7-(4-chloro-2-hydroxyphenyl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=CC=1C1=C(C=C(C=C1)Cl)O)N1CCN(CC1)C(C=C)=O FXRQIENUNKJYLX-UHFFFAOYSA-N 0.000 claims 1
- FYJIGFIDDKMMEW-UHFFFAOYSA-N 1-[4-[6-chloro-7-(4-chlorophenyl)isoquinolin-1-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C=CN=C(C2=CC=1C1=CC=C(C=C1)Cl)N1CCN(CC1)C(C=C)=O FYJIGFIDDKMMEW-UHFFFAOYSA-N 0.000 claims 1
- DFEZCFPYGAAROG-UHFFFAOYSA-N 1-[4-[6-chloro-7-(4-chlorophenyl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=CC=1C1=CC=C(C=C1)Cl)N1CCN(CC1)C(C=C)=O DFEZCFPYGAAROG-UHFFFAOYSA-N 0.000 claims 1
- CVYFMLRCXKOPIY-UHFFFAOYSA-N 1-[4-[6-chloro-7-(4-fluorophenyl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=CC=1C1=CC=C(C=C1)F)N1CCN(CC1)C(C=C)=O CVYFMLRCXKOPIY-UHFFFAOYSA-N 0.000 claims 1
- XEHOOVBSSXZCHD-UHFFFAOYSA-N 1-[4-[6-chloro-7-(5,6,7,8-tetrahydronaphthalen-1-yl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=CC=1C1=CC=CC=2CCCCC1=2)N1CCN(CC1)C(C=C)=O XEHOOVBSSXZCHD-UHFFFAOYSA-N 0.000 claims 1
- YKWIGTCLBDPDJQ-UHFFFAOYSA-N 1-[4-[6-chloro-7-(5,6-dimethyl-1H-indazol-7-yl)-8-fluoroquinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound CC1=CC2=C(NN=C2)C(=C1C)C1=C(Cl)C=C2C(=NC=NC2=C1F)N1CCN(CC1)C(=O)C=C YKWIGTCLBDPDJQ-UHFFFAOYSA-N 0.000 claims 1
- MVMPKXSISRRKBY-UHFFFAOYSA-N 1-[4-[6-chloro-7-(5-chloro-1H-indazol-7-yl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=CC=1C=1C=C(C=C2C=NNC=12)Cl)N1CCN(CC1)C(C=C)=O MVMPKXSISRRKBY-UHFFFAOYSA-N 0.000 claims 1
- IMKWJMQQVWCVJF-UHFFFAOYSA-N 1-[4-[6-chloro-7-(5-chloro-2-fluorophenyl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=CC=1C1=C(C=CC(=C1)Cl)F)N1CCN(CC1)C(C=C)=O IMKWJMQQVWCVJF-UHFFFAOYSA-N 0.000 claims 1
- REDGHFHIRSCTTC-UHFFFAOYSA-N 1-[4-[6-chloro-7-(5-fluoro-2-hydroxyphenyl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=CC=1C1=C(C=CC(=C1)F)O)N1CCN(CC1)C(C=C)=O REDGHFHIRSCTTC-UHFFFAOYSA-N 0.000 claims 1
- MCPXKPOTEYNDPT-UHFFFAOYSA-N 1-[4-[6-chloro-7-(5-methoxy-1H-indazol-4-yl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=CC=1C1=C2C=NNC2=CC=C1OC)N1CCN(CC1)C(C=C)=O MCPXKPOTEYNDPT-UHFFFAOYSA-N 0.000 claims 1
- RUNNTCOZWWNTIP-UHFFFAOYSA-N 1-[4-[6-chloro-7-(5-methyl-1H-indazol-4-yl)cinnolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound Cc1ccc2[nH]ncc2c1-c1cc2nncc(N3CCN(CC3)C(=O)C=C)c2cc1Cl RUNNTCOZWWNTIP-UHFFFAOYSA-N 0.000 claims 1
- LVJNMZYXVYJJDZ-UHFFFAOYSA-N 1-[4-[6-chloro-7-(6-chloro-1H-indazol-4-yl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=CC=1C1=C2C=NNC2=CC(=C1)Cl)N1CCN(CC1)C(C=C)=O LVJNMZYXVYJJDZ-UHFFFAOYSA-N 0.000 claims 1
- CGJURDBMOPNKHP-UHFFFAOYSA-N 1-[4-[6-chloro-7-(6-methyl-1H-indazol-4-yl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound CC1=CC2=C(C=NN2)C(=C1)C1=C(Cl)C=C2C(=C1)N=CN=C2N1CCN(CC1)C(=O)C=C CGJURDBMOPNKHP-UHFFFAOYSA-N 0.000 claims 1
- PFDBJNUZRXGTAR-UHFFFAOYSA-N 1-[4-[6-chloro-7-(6-methyl-1H-indazol-7-yl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=CC=1C=1C(=CC=C2C=NNC=12)C)N1CCN(CC1)C(C=C)=O PFDBJNUZRXGTAR-UHFFFAOYSA-N 0.000 claims 1
- VZKMGVIKFOHCJC-UHFFFAOYSA-N 1-[4-[6-chloro-7-[2-(1,3-thiazol-5-yl)phenyl]quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=CC=1C1=C(C=CC=C1)C1=CN=CS1)N1CCN(CC1)C(C=C)=O VZKMGVIKFOHCJC-UHFFFAOYSA-N 0.000 claims 1
- QKRGGXZBKYPGIH-UHFFFAOYSA-N 1-[4-[6-chloro-7-[2-(1-methylcyclopropyl)phenyl]quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=CC=1C1=C(C=CC=C1)C1(CC1)C)N1CCN(CC1)C(C=C)=O QKRGGXZBKYPGIH-UHFFFAOYSA-N 0.000 claims 1
- RUMMUILTEBXPCR-UHFFFAOYSA-N 1-[4-[6-chloro-7-[2-(1H-pyrazol-4-yl)phenyl]quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound N1N=CC(=C1)C1=C(C=CC=C1)C1=C(C=C2C(=NC=NC2=C1)N1CCN(CC1)C(C=C)=O)Cl RUMMUILTEBXPCR-UHFFFAOYSA-N 0.000 claims 1
- BGIOAJNOPPPBHB-UHFFFAOYSA-N 1-[4-[6-chloro-7-[2-(hydroxymethyl)phenyl]quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=CC=1C1=C(C=CC=C1)CO)N1CCN(CC1)C(C=C)=O BGIOAJNOPPPBHB-UHFFFAOYSA-N 0.000 claims 1
- GMUQUXNKNCSOJM-UHFFFAOYSA-N 1-[4-[6-chloro-7-[2-(trifluoromethyl)phenyl]cinnolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=CN=NC2=CC=1C1=C(C=CC=C1)C(F)(F)F)N1CCN(CC1)C(C=C)=O GMUQUXNKNCSOJM-UHFFFAOYSA-N 0.000 claims 1
- JVAOFSJEYPKTSP-UHFFFAOYSA-N 1-[4-[6-chloro-7-[2-(trifluoromethyl)phenyl]quinazolin-4-yl]-2-methylpiperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=CC=1C1=C(C=CC=C1)C(F)(F)F)N1CC(N(CC1)C(C=C)=O)C JVAOFSJEYPKTSP-UHFFFAOYSA-N 0.000 claims 1
- FSYCXERZSLCXBW-UHFFFAOYSA-N 1-[4-[6-chloro-7-[2-(trifluoromethyl)phenyl]quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=CC=1C1=C(C=CC=C1)C(F)(F)F)N1CCN(CC1)C(C=C)=O FSYCXERZSLCXBW-UHFFFAOYSA-N 0.000 claims 1
- AAEKVEINEZICAS-UHFFFAOYSA-N 1-[4-[6-chloro-7-[2-[(dimethylamino)methyl]-6-fluorophenyl]-8-fluoroquinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=C(C=1C1=C(C=CC=C1F)CN(C)C)F)N1CCN(CC1)C(C=C)=O AAEKVEINEZICAS-UHFFFAOYSA-N 0.000 claims 1
- LKNAEWXCWLLJML-UHFFFAOYSA-N 1-[4-[6-chloro-7-[2-fluoro-5-(2-hydroxypropan-2-yl)phenyl]quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=CC=1C1=C(C=CC(=C1)C(C)(C)O)F)N1CCN(CC1)C(C=C)=O LKNAEWXCWLLJML-UHFFFAOYSA-N 0.000 claims 1
- FWYWFFYCMGFDIK-UHFFFAOYSA-N 1-[4-[6-chloro-7-[2-fluoro-5-(trifluoromethoxy)phenyl]quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=CC=1C1=C(C=CC(=C1)OC(F)(F)F)F)N1CCN(CC1)C(C=C)=O FWYWFFYCMGFDIK-UHFFFAOYSA-N 0.000 claims 1
- ZLELLBCRLPCOFT-UHFFFAOYSA-N 1-[4-[6-chloro-7-[2-methyl-5-(methylamino)phenyl]quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=CC=1C1=C(C=CC(=C1)NC)C)N1CCN(CC1)C(C=C)=O ZLELLBCRLPCOFT-UHFFFAOYSA-N 0.000 claims 1
- QTJOFFMPHKBEQJ-UHFFFAOYSA-N 1-[4-[6-chloro-7-[3-(1H-pyrazol-5-yl)phenyl]quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound N1N=CC=C1C=1C=C(C=CC=1)C1=C(C=C2C(=NC=NC2=C1)N1CCN(CC1)C(C=C)=O)Cl QTJOFFMPHKBEQJ-UHFFFAOYSA-N 0.000 claims 1
- MCJQRNXHTQCQQB-UHFFFAOYSA-N 1-[4-[6-chloro-7-[3-(difluoromethyl)naphthalen-1-yl]-8-fluoroquinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound FC(F)C1=CC2=C(C=CC=C2)C(=C1)C1=C(Cl)C=C2C(=NC=NC2=C1F)N1CCN(CC1)C(=O)C=C MCJQRNXHTQCQQB-UHFFFAOYSA-N 0.000 claims 1
- MEYJMMLRYJABBW-UHFFFAOYSA-N 1-[4-[6-chloro-7-[4-hydroxy-2-(trifluoromethyl)phenyl]quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=CC=1C1=C(C=C(C=C1)O)C(F)(F)F)N1CCN(CC1)C(C=C)=O MEYJMMLRYJABBW-UHFFFAOYSA-N 0.000 claims 1
- YXRHLRXGGREZKI-UHFFFAOYSA-N 1-[4-[6-chloro-7-[5-(difluoromethyl)-2-fluorophenyl]-8-fluoroquinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=C(C=1C1=C(C=CC(=C1)C(F)F)F)F)N1CCN(CC1)C(C=C)=O YXRHLRXGGREZKI-UHFFFAOYSA-N 0.000 claims 1
- XVWAUODEBBYQAK-UHFFFAOYSA-N 1-[4-[6-chloro-8-fluoro-2-(2-hydroxyethylamino)-7-(3-hydroxynaphthalen-1-yl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC(=NC2=C(C=1C1=CC(=CC2=CC=CC=C12)O)F)NCCO)N1CCN(CC1)C(C=C)=O XVWAUODEBBYQAK-UHFFFAOYSA-N 0.000 claims 1
- QUYKZLZICATLES-UHFFFAOYSA-N 1-[4-[6-chloro-8-fluoro-2-(methylamino)-7-(5-methyl-1H-indazol-4-yl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC(=NC2=C(C=1C1=C2C=NNC2=CC=C1C)F)NC)N1CCN(CC1)C(C=C)=O QUYKZLZICATLES-UHFFFAOYSA-N 0.000 claims 1
- DLYXGTXMBXYNAW-UHFFFAOYSA-N 1-[4-[6-chloro-8-fluoro-7-(2-fluorophenyl)quinazolin-4-yl]-2-ethynylpiperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=C(C=1C1=C(C=CC=C1)F)F)N1CC(N(CC1)C(C=C)=O)C#C DLYXGTXMBXYNAW-UHFFFAOYSA-N 0.000 claims 1
- RTHLFZDWPYVCCE-UHFFFAOYSA-N 1-[4-[6-chloro-8-fluoro-7-(2-fluorophenyl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=C(C=1C1=C(C=CC=C1)F)F)N1CCN(CC1)C(C=C)=O RTHLFZDWPYVCCE-UHFFFAOYSA-N 0.000 claims 1
- YJWJJXIBHVCPHU-UHFFFAOYSA-N 1-[4-[6-chloro-8-fluoro-7-(2-methoxy-6-methylphenyl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=C(C=1C1=C(C=CC=C1C)OC)F)N1CCN(CC1)C(C=C)=O YJWJJXIBHVCPHU-UHFFFAOYSA-N 0.000 claims 1
- RPXCNCRDXKTEHQ-UHFFFAOYSA-N 1-[4-[6-chloro-8-fluoro-7-(3-hydroxynaphthalen-1-yl)-2-(methylamino)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound CNC1=NC2=C(F)C(=C(Cl)C=C2C(=N1)N1CCN(CC1)C(=O)C=C)C1=CC(O)=CC2=C1C=CC=C2 RPXCNCRDXKTEHQ-UHFFFAOYSA-N 0.000 claims 1
- NRZSFXBVYWTKEW-UHFFFAOYSA-N 1-[4-[6-chloro-8-fluoro-7-(3-hydroxynaphthalen-1-yl)-2-[(1-methylpyrrolidin-3-yl)amino]quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC(=NC2=C(C=1C1=CC(=CC2=CC=CC=C12)O)F)NC1CN(CC1)C)N1CCN(CC1)C(C=C)=O NRZSFXBVYWTKEW-UHFFFAOYSA-N 0.000 claims 1
- MWXSVVVDZNMBKY-UHFFFAOYSA-N 1-[4-[6-chloro-8-fluoro-7-(3-hydroxynaphthalen-1-yl)quinazolin-4-yl]-2-(hydroxymethyl)piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=C(C=1C1=CC(=CC2=CC=CC=C12)O)F)N1CC(N(CC1)C(C=C)=O)CO MWXSVVVDZNMBKY-UHFFFAOYSA-N 0.000 claims 1
- QJJHZXDTCSGYQM-UHFFFAOYSA-N 1-[4-[6-chloro-8-fluoro-7-(3-hydroxynaphthalen-1-yl)quinazolin-4-yl]-2-[(dimethylamino)methyl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=C(C=1C1=CC(=CC2=CC=CC=C12)O)F)N1CC(N(CC1)C(C=C)=O)CN(C)C QJJHZXDTCSGYQM-UHFFFAOYSA-N 0.000 claims 1
- JIPIHCUZVBBERR-UHFFFAOYSA-N 1-[4-[6-chloro-8-fluoro-7-(3-hydroxynaphthalen-1-yl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=C(C=1C1=CC(=CC2=CC=CC=C12)O)F)N1CCN(CC1)C(C=C)=O JIPIHCUZVBBERR-UHFFFAOYSA-N 0.000 claims 1
- RTDBXHABGLDADS-UHFFFAOYSA-N 1-[4-[6-chloro-8-fluoro-7-(5-fluoro-1H-indazol-4-yl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=C(C=1C1=C2C=NNC2=CC=C1F)F)N1CCN(CC1)C(C=C)=O RTDBXHABGLDADS-UHFFFAOYSA-N 0.000 claims 1
- LUQQDERCFJFBBQ-UHFFFAOYSA-N 1-[4-[6-chloro-8-fluoro-7-(5-methyl-1H-indazol-4-yl)-2-(1,3-thiazol-5-yl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound Cc1ccc2[nH]ncc2c1-c1c(Cl)cc2c(nc(nc2c1F)-c1cncs1)N1CCN(CC1)C(=O)C=C LUQQDERCFJFBBQ-UHFFFAOYSA-N 0.000 claims 1
- KJOSGVXPZYUQIR-UHFFFAOYSA-N 1-[4-[6-chloro-8-fluoro-7-(5-methyl-1H-indazol-4-yl)-2-(1-methylpyrazol-4-yl)oxyquinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC(=NC2=C(C=1C1=C2C=NNC2=CC=C1C)F)OC=1C=NN(C=1)C)N1CCN(CC1)C(C=C)=O KJOSGVXPZYUQIR-UHFFFAOYSA-N 0.000 claims 1
- PFQFOPLDZBTYCC-UHFFFAOYSA-N 1-[4-[6-chloro-8-fluoro-7-(5-methyl-1H-indazol-4-yl)-2-(1H-pyrazol-5-yl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC(=NC2=C(C=1C1=C2C=NNC2=CC=C1C)F)C1=CC=NN1)N1CCN(CC1)C(C=C)=O PFQFOPLDZBTYCC-UHFFFAOYSA-N 0.000 claims 1
- HHFMAIRRWYCXLS-UHFFFAOYSA-N 1-[4-[6-chloro-8-fluoro-7-(5-methyl-1H-indazol-4-yl)-2-(2-morpholin-4-ylethoxy)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC(=NC2=C(C=1C1=C2C=NNC2=CC=C1C)F)OCCN1CCOCC1)N1CCN(CC1)C(C=C)=O HHFMAIRRWYCXLS-UHFFFAOYSA-N 0.000 claims 1
- PQEAOXGIWOXHRW-UHFFFAOYSA-N 1-[4-[6-chloro-8-fluoro-7-(5-methyl-1H-indazol-4-yl)-2-(2-pyrrolidin-1-ylethoxy)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC(=NC2=C(C=1C1=C2C=NNC2=CC=C1C)F)OCCN1CCCC1)N1CCN(CC1)C(C=C)=O PQEAOXGIWOXHRW-UHFFFAOYSA-N 0.000 claims 1
- HKNSISVRNYUYFR-UHFFFAOYSA-N 1-[4-[6-chloro-8-fluoro-7-(5-methyl-1H-indazol-4-yl)-2-[(1-methylpiperidin-4-yl)amino]quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC(=NC2=C(C=1C1=C2C=NNC2=CC=C1C)F)NC1CCN(CC1)C)N1CCN(CC1)C(C=C)=O HKNSISVRNYUYFR-UHFFFAOYSA-N 0.000 claims 1
- PHELBDYDPSAWJB-UHFFFAOYSA-N 1-[4-[6-chloro-8-fluoro-7-(5-methyl-1H-indazol-4-yl)-2-[(1-methylpyrrolidin-3-yl)amino]quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC(=NC2=C(C=1C1=C2C=NNC2=CC=C1C)F)NC1CN(CC1)C)N1CCN(CC1)C(C=C)=O PHELBDYDPSAWJB-UHFFFAOYSA-N 0.000 claims 1
- YKSFNPHAFKOVIT-UHFFFAOYSA-N 1-[4-[6-chloro-8-fluoro-7-(5-methyl-1H-indazol-4-yl)-2-[2-(4-methylpiperazin-1-yl)ethoxy]quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC(=NC2=C(C=1C1=C2C=NNC2=CC=C1C)F)OCCN1CCN(CC1)C)N1CCN(CC1)C(C=C)=O YKSFNPHAFKOVIT-UHFFFAOYSA-N 0.000 claims 1
- LZEAGRNJGRQMAA-UHFFFAOYSA-N 1-[4-[6-chloro-8-fluoro-7-(6-fluoro-1H-indazol-7-yl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=C(C=1C=1C(=CC=C2C=NNC=12)F)F)N1CCN(CC1)C(C=C)=O LZEAGRNJGRQMAA-UHFFFAOYSA-N 0.000 claims 1
- BCFVCUHDMXEJOF-UHFFFAOYSA-N 1-[4-[6-chloro-8-fluoro-7-(6-methyl-1H-indazol-7-yl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=C(C=1C=1C(=CC=C2C=NNC=12)C)F)N1CCN(CC1)C(C=C)=O BCFVCUHDMXEJOF-UHFFFAOYSA-N 0.000 claims 1
- IXWAUFLCOHGFEX-UHFFFAOYSA-N 1-[4-[6-chloro-8-fluoro-7-[2-(2-hydroxypropan-2-yl)phenyl]quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=C(C=1C1=C(C=CC=C1)C(C)(C)O)F)N1CCN(CC1)C(C=C)=O IXWAUFLCOHGFEX-UHFFFAOYSA-N 0.000 claims 1
- BPLQGLVADWUFLY-UHFFFAOYSA-N 1-[4-[6-chloro-8-fluoro-7-[2-(trifluoromethyl)phenyl]quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=C(C=1C1=C(C=CC=C1)C(F)(F)F)F)N1CCN(CC1)C(C=C)=O BPLQGLVADWUFLY-UHFFFAOYSA-N 0.000 claims 1
- IVVWPYMATKEUQO-UHFFFAOYSA-N 1-[4-[6-chloro-8-fluoro-7-[2-fluoro-5-(1H-imidazol-5-yl)phenyl]quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=C(C=1C1=C(C=CC(=C1)C=1N=CNC=1)F)F)N1CCN(CC1)C(C=C)=O IVVWPYMATKEUQO-UHFFFAOYSA-N 0.000 claims 1
- YWUACZJSIZFOMW-UHFFFAOYSA-N 1-[4-[6-chloro-8-methoxy-7-(5-methyl-1H-indazol-4-yl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC=1C=C2C(=NC=NC2=C(C=1C1=C2C=NNC2=CC=C1C)OC)N1CCN(CC1)C(C=C)=O YWUACZJSIZFOMW-UHFFFAOYSA-N 0.000 claims 1
- QUGAPSNKNWDTOU-UHFFFAOYSA-N 1-[4-[7-(1,3-benzoxazol-7-yl)-6-chloroquinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound O1C=NC2=C1C(=CC=C2)C1=C(C=C2C(=NC=NC2=C1)N1CCN(CC1)C(C=C)=O)Cl QUGAPSNKNWDTOU-UHFFFAOYSA-N 0.000 claims 1
- DFTSOTGDOFGJTF-UHFFFAOYSA-N 1-[4-[7-(1H-benzimidazol-4-yl)-6-chloroquinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound N1C=NC2=C1C=CC=C2C1=C(C=C2C(=NC=NC2=C1)N1CCN(CC1)C(C=C)=O)Cl DFTSOTGDOFGJTF-UHFFFAOYSA-N 0.000 claims 1
- KRAFXPZCSRNNAM-UHFFFAOYSA-N 1-[4-[7-(2,4-difluorophenyl)-6,8-difluoroquinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound Fc1ccc(c(F)c1)-c1c(F)cc2c(ncnc2c1F)N1CCN(CC1)C(=O)C=C KRAFXPZCSRNNAM-UHFFFAOYSA-N 0.000 claims 1
- GXLLVQPUXRMPLE-UHFFFAOYSA-N 1-[4-[7-(2,4-difluorophenyl)-6-(trifluoromethyl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound FC1=C(C=CC(=C1)F)C1=C(C=C2C(=NC=NC2=C1)N1CCN(CC1)C(C=C)=O)C(F)(F)F GXLLVQPUXRMPLE-UHFFFAOYSA-N 0.000 claims 1
- DOVGHQNGQPGQHU-UHFFFAOYSA-N 1-[4-[7-(2,4-difluorophenyl)-8-fluoro-6-methylquinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound Cc1cc2c(ncnc2c(F)c1-c1ccc(F)cc1F)N1CCN(CC1)C(=O)C=C DOVGHQNGQPGQHU-UHFFFAOYSA-N 0.000 claims 1
- OQYUPEIJIZGKLP-UHFFFAOYSA-N 1-[4-[7-(2-amino-1,3-benzoxazol-5-yl)-6-chloroquinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound NC=1OC2=C(N=1)C=C(C=C2)C1=C(C=C2C(=NC=NC2=C1)N1CCN(CC1)C(C=C)=O)Cl OQYUPEIJIZGKLP-UHFFFAOYSA-N 0.000 claims 1
- URDILORWFOILAY-UHFFFAOYSA-N 1-[4-[7-(2-amino-5-methylpyrimidin-4-yl)-6-chloroquinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound NC1=NC=C(C(=N1)C1=C(C=C2C(=NC=NC2=C1)N1CCN(CC1)C(C=C)=O)Cl)C URDILORWFOILAY-UHFFFAOYSA-N 0.000 claims 1
- ABZMUQANXKWHBX-UHFFFAOYSA-N 1-[4-[7-(2-chloro-5-hydroxyphenyl)-6-(trifluoromethyl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC1=C(C=C(C=C1)O)C1=C(C=C2C(=NC=NC2=C1)N1CCN(CC1)C(C=C)=O)C(F)(F)F ABZMUQANXKWHBX-UHFFFAOYSA-N 0.000 claims 1
- PXBGIHXERTUJEA-UHFFFAOYSA-N 1-[4-[7-(2-fluoro-6-hydroxyphenyl)-6-(trifluoromethyl)cinnolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound Oc1cccc(F)c1-c1cc2nncc(N3CCN(CC3)C(=O)C=C)c2cc1C(F)(F)F PXBGIHXERTUJEA-UHFFFAOYSA-N 0.000 claims 1
- RVKPORQTCUUODU-UHFFFAOYSA-N 1-[4-[7-(2-fluoro-6-hydroxyphenyl)-6-(trifluoromethyl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound FC1=C(C(=CC=C1)O)C1=C(C=C2C(=NC=NC2=C1)N1CCN(CC1)C(C=C)=O)C(F)(F)F RVKPORQTCUUODU-UHFFFAOYSA-N 0.000 claims 1
- NIGMLNOVECNYFO-UHFFFAOYSA-N 1-[4-[7-(2-fluorophenyl)-6-hydroxyquinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound Oc1cc2c(ncnc2cc1-c1ccccc1F)N1CCN(CC1)C(=O)C=C NIGMLNOVECNYFO-UHFFFAOYSA-N 0.000 claims 1
- KPYCUKBFUITQPF-UHFFFAOYSA-N 1-[4-[7-(2-hydroxynaphthalen-1-yl)-6-(trifluoromethyl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound OC1=C(C2=CC=CC=C2C=C1)C1=C(C=C2C(=NC=NC2=C1)N1CCN(CC1)C(C=C)=O)C(F)(F)F KPYCUKBFUITQPF-UHFFFAOYSA-N 0.000 claims 1
- GUCNCDWEKSLEBC-UHFFFAOYSA-N 1-[4-[7-(3-amino-1,2-benzoxazol-4-yl)-6-chloroquinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound NC1=NOC2=C1C(=CC=C2)C1=C(C=C2C(=NC=NC2=C1)N1CCN(CC1)C(C=C)=O)Cl GUCNCDWEKSLEBC-UHFFFAOYSA-N 0.000 claims 1
- PWRBWYHNAXAARN-UHFFFAOYSA-N 1-[4-[7-(3-hydroxynaphthalen-1-yl)-6-(trifluoromethyl)cinnolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound OC=1C=C(C2=CC=CC=C2C=1)C1=C(C=C2C(=CN=NC2=C1)N1CCN(CC1)C(C=C)=O)C(F)(F)F PWRBWYHNAXAARN-UHFFFAOYSA-N 0.000 claims 1
- HAJUVCFSXQGBQD-UHFFFAOYSA-N 1-[4-[7-(5-methyl-1H-indazol-4-yl)-6-(trifluoromethyl)cinnolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound CC=1C(=C2C=NNC2=CC=1)C1=C(C=C2C(=CN=NC2=C1)N1CCN(CC1)C(C=C)=O)C(F)(F)F HAJUVCFSXQGBQD-UHFFFAOYSA-N 0.000 claims 1
- SYRYMOQJYDVNEO-UHFFFAOYSA-N 1-[4-[7-(5-methyl-1H-indazol-4-yl)-6-(trifluoromethyl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound CC=1C(=C2C=NNC2=CC=1)C1=C(C=C2C(=NC=NC2=C1)N1CCN(CC1)C(C=C)=O)C(F)(F)F SYRYMOQJYDVNEO-UHFFFAOYSA-N 0.000 claims 1
- WNLHCLQLOCQUOP-UHFFFAOYSA-N 1-[4-[7-[2-(trifluoromethyl)phenyl]quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound FC(C1=C(C=CC=C1)C1=CC=C2C(=NC=NC2=C1)N1CCN(CC1)C(C=C)=O)(F)F WNLHCLQLOCQUOP-UHFFFAOYSA-N 0.000 claims 1
- BVCJWYJYLNZYJX-UHFFFAOYSA-N 1-[4-[7-chloro-6-(2,5-dichlorophenyl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC1=CC(=C(Cl)C=C1)C1=C(Cl)C=C2N=CN=C(N3CCN(CC3)C(=O)C=C)C2=C1 BVCJWYJYLNZYJX-UHFFFAOYSA-N 0.000 claims 1
- OMBGOMDFEOQGAD-UHFFFAOYSA-N 1-[4-[7-chloro-6-(2-chloro-5-fluorophenyl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC1=C(C=C2C(=NC=NC2=C1)N1CCN(CC1)C(C=C)=O)C1=C(C=CC(=C1)F)Cl OMBGOMDFEOQGAD-UHFFFAOYSA-N 0.000 claims 1
- RSVUKPRLFYMBPZ-UHFFFAOYSA-N 1-[4-[7-chloro-6-(2-chlorophenyl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound Clc1ccccc1-c1cc2c(ncnc2cc1Cl)N1CCN(CC1)C(=O)C=C RSVUKPRLFYMBPZ-UHFFFAOYSA-N 0.000 claims 1
- UATGUDBUCPYXNM-UHFFFAOYSA-N 1-[4-[7-chloro-6-(2-hydroxyphenyl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound OC1=C(C=CC=C1)C1=C(Cl)C=C2N=CN=C(N3CCN(CC3)C(=O)C=C)C2=C1 UATGUDBUCPYXNM-UHFFFAOYSA-N 0.000 claims 1
- YSMYGXLFWKFBSE-UHFFFAOYSA-N 1-[4-[7-chloro-6-(3,4-dichlorophenyl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC1=C(C=C2C(=NC=NC2=C1)N1CCN(CC1)C(C=C)=O)C1=CC(=C(C=C1)Cl)Cl YSMYGXLFWKFBSE-UHFFFAOYSA-N 0.000 claims 1
- QUBHXBPPKHCBJO-UHFFFAOYSA-N 1-[4-[7-chloro-6-(3-chlorophenyl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC1=C(C=C2C(=NC=NC2=C1)N1CCN(CC1)C(C=C)=O)C1=CC(=CC=C1)Cl QUBHXBPPKHCBJO-UHFFFAOYSA-N 0.000 claims 1
- IJJHOCZHFKNJNJ-UHFFFAOYSA-N 1-[4-[7-chloro-6-(3-hydroxyphenyl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC1=C(C=C2C(=NC=NC2=C1)N1CCN(CC1)C(C=C)=O)C1=CC(=CC=C1)O IJJHOCZHFKNJNJ-UHFFFAOYSA-N 0.000 claims 1
- VPODTNMHLSACQK-UHFFFAOYSA-N 1-[4-[7-chloro-6-(4-chloro-2-hydroxyphenyl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound OC1=C(C=CC(Cl)=C1)C1=C(Cl)C=C2N=CN=C(N3CCN(CC3)C(=O)C=C)C2=C1 VPODTNMHLSACQK-UHFFFAOYSA-N 0.000 claims 1
- FHWRZQDMIREABM-UHFFFAOYSA-N 1-[4-[7-chloro-6-(4-chlorophenyl)-2-methoxyquinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound COc1nc(N2CCN(CC2)C(=O)C=C)c2cc(c(Cl)cc2n1)-c1ccc(Cl)cc1 FHWRZQDMIREABM-UHFFFAOYSA-N 0.000 claims 1
- UDKAYUJMKNQOOF-UHFFFAOYSA-N 1-[4-[7-chloro-6-(4-chlorophenyl)-2-methylquinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound Cc1nc(N2CCN(CC2)C(=O)C=C)c2cc(c(Cl)cc2n1)-c1ccc(Cl)cc1 UDKAYUJMKNQOOF-UHFFFAOYSA-N 0.000 claims 1
- CQXAQQOFPAPOKT-UHFFFAOYSA-N 1-[4-[7-chloro-6-(4-chlorophenyl)quinazolin-4-yl]-2-(2-hydroxyethyl)piperazin-1-yl]prop-2-en-1-one Chemical compound OCCC1CN(CCN1C(=O)C=C)c1ncnc2cc(Cl)c(cc12)-c1ccc(Cl)cc1 CQXAQQOFPAPOKT-UHFFFAOYSA-N 0.000 claims 1
- DHBIGKJOXCGDPD-UHFFFAOYSA-N 1-[4-[7-chloro-6-(4-chlorophenyl)quinazolin-4-yl]-2-[(dimethylamino)methyl]piperazin-1-yl]prop-2-en-1-one Chemical compound CN(C)CC1CN(CCN1C(=O)C=C)c1ncnc2cc(Cl)c(cc12)-c1ccc(Cl)cc1 DHBIGKJOXCGDPD-UHFFFAOYSA-N 0.000 claims 1
- BVNXGHZFCUJIBG-UHFFFAOYSA-N 1-[4-[7-chloro-6-(4-hydroxyphenyl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound ClC1=C(C=C2C(=NC=NC2=C1)N1CCN(CC1)C(C=C)=O)C1=CC=C(C=C1)O BVNXGHZFCUJIBG-UHFFFAOYSA-N 0.000 claims 1
- PXPJDNUBFUAITJ-UHFFFAOYSA-N 1-[4-[7-cyclopropyl-6-(4-cyclopropylphenyl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound C1(CC1)C1=C(C=C2C(=NC=NC2=C1)N1CCN(CC1)C(C=C)=O)C1=CC=C(C=C1)C1CC1 PXPJDNUBFUAITJ-UHFFFAOYSA-N 0.000 claims 1
- ACAVOXZNLGUVFO-UHFFFAOYSA-N 1-[4-[8-fluoro-7-(2-fluorophenyl)-6-(trifluoromethyl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one Chemical compound Fc1ccccc1-c1c(F)c2ncnc(N3CCN(CC3)C(=O)C=C)c2cc1C(F)(F)F ACAVOXZNLGUVFO-UHFFFAOYSA-N 0.000 claims 1
- QKOBJQWOZRHSHK-UHFFFAOYSA-N 1-[4-[[6-chloro-5-(2-chlorophenyl)-1H-indazol-3-yl]amino]piperidin-1-yl]prop-2-en-1-one Chemical compound Clc1ccccc1-c1cc2c(NC3CCN(CC3)C(=O)C=C)n[nH]c2cc1Cl QKOBJQWOZRHSHK-UHFFFAOYSA-N 0.000 claims 1
- HEOGLXRQJWSWSS-UHFFFAOYSA-N 1-[4-[[7-chloro-6-(2-chlorophenyl)quinazolin-4-yl]amino]piperidin-1-yl]prop-2-en-1-one Chemical compound ClC1=C(C=C2C(=NC=NC2=C1)NC1CCN(CC1)C(C=C)=O)C1=C(C=CC=C1)Cl HEOGLXRQJWSWSS-UHFFFAOYSA-N 0.000 claims 1
- SCRXBLNEMXWBGH-UHFFFAOYSA-N 1-prop-2-enoyl-4-quinazolin-4-ylpiperazine-2-carbonitrile Chemical compound C(C=C)(=O)N1C(CN(CC1)C1=NC=NC2=CC=CC=C12)C#N SCRXBLNEMXWBGH-UHFFFAOYSA-N 0.000 claims 1
- CCLFMWKMBLVHQE-UHFFFAOYSA-N 2-[2-[6-chloro-4-(4-prop-2-enoylpiperazin-1-yl)quinazolin-7-yl]phenyl]acetonitrile Chemical compound C(C=C)(=O)N1CCN(CC1)C1=NC=NC2=CC(=C(C=C12)Cl)C1=C(C=CC=C1)CC#N CCLFMWKMBLVHQE-UHFFFAOYSA-N 0.000 claims 1
- WESPEBFRBSHGNW-UHFFFAOYSA-N 2-[4-(6-chloro-7-phenylquinazolin-4-yl)-1-prop-2-enoylpiperazin-2-yl]acetonitrile Chemical compound C(C=C)(=O)N1C(CN(CC1)C1=NC=NC2=CC(=C(C=C12)Cl)C1=CC=CC=C1)CC#N WESPEBFRBSHGNW-UHFFFAOYSA-N 0.000 claims 1
- RLHHVJVCKJQCAH-UHFFFAOYSA-N 2-[4-[6-chloro-7-(2,4-difluorophenyl)quinazolin-4-yl]-1-prop-2-enoylpiperazin-2-yl]acetonitrile Chemical compound C(C=C)(=O)N1C(CN(CC1)C1=NC=NC2=CC(=C(C=C12)Cl)C1=C(C=C(C=C1)F)F)CC#N RLHHVJVCKJQCAH-UHFFFAOYSA-N 0.000 claims 1
- SJIOQBWCURFASK-UHFFFAOYSA-N 2-[4-[6-chloro-7-(2-chlorophenyl)quinazolin-4-yl]-1-prop-2-enoylpiperazin-2-yl]acetonitrile Chemical compound C(C=C)(=O)N1C(CN(CC1)C1=NC=NC2=CC(=C(C=C12)Cl)C1=C(C=CC=C1)Cl)CC#N SJIOQBWCURFASK-UHFFFAOYSA-N 0.000 claims 1
- RYIUTLAVNDPKBW-UHFFFAOYSA-N 2-[4-[6-chloro-7-(2-ethylphenyl)quinazolin-4-yl]-1-prop-2-enoylpiperazin-2-yl]acetonitrile Chemical compound C(C=C)(=O)N1C(CN(CC1)C1=NC=NC2=CC(=C(C=C12)Cl)C1=C(C=CC=C1)CC)CC#N RYIUTLAVNDPKBW-UHFFFAOYSA-N 0.000 claims 1
- CNSHQUXCOFGLIQ-UHFFFAOYSA-N 2-[4-[6-chloro-7-(4-chlorophenyl)quinazolin-4-yl]-1-prop-2-enoylpiperazin-2-yl]acetonitrile Chemical compound C(C=C)(=O)N1C(CN(CC1)C1=NC=NC2=CC(=C(C=C12)Cl)C1=CC=C(C=C1)Cl)CC#N CNSHQUXCOFGLIQ-UHFFFAOYSA-N 0.000 claims 1
- KIVGPONNZNNPNN-UHFFFAOYSA-N 2-[4-[6-chloro-8-fluoro-7-(5-methyl-1H-indazol-4-yl)quinazolin-4-yl]-1-prop-2-enoylpiperazin-2-yl]acetonitrile Chemical compound C(C=C)(=O)N1C(CN(CC1)C1=NC=NC2=C(C(=C(C=C12)Cl)C1=C2C=NNC2=CC=C1C)F)CC#N KIVGPONNZNNPNN-UHFFFAOYSA-N 0.000 claims 1
- KZOIGRMCBGIUJH-UHFFFAOYSA-N 2-[4-[6-chloro-8-fluoro-7-[2-(trifluoromethyl)phenyl]quinazolin-4-yl]-1-prop-2-enoylpiperazin-2-yl]acetonitrile Chemical compound C(C=C)(=O)N1C(CN(CC1)C1=NC=NC2=C(C(=C(C=C12)Cl)C1=C(C=CC=C1)C(F)(F)F)F)CC#N KZOIGRMCBGIUJH-UHFFFAOYSA-N 0.000 claims 1
- VDJPXWHCVCRKNH-UHFFFAOYSA-N 2-[4-[7-chloro-6-(4-chlorophenyl)quinazolin-4-yl]-1-prop-2-enoylpiperazin-2-yl]acetonitrile Chemical compound Clc1ccc(cc1)-c1cc2c(ncnc2cc1Cl)N1CCN(C(CC#N)C1)C(=O)C=C VDJPXWHCVCRKNH-UHFFFAOYSA-N 0.000 claims 1
- AYCKHIMPCUTHOI-UHFFFAOYSA-N 2-[6-chloro-4-(4-prop-2-enoylpiperazin-1-yl)quinazolin-7-yl]-3-fluorobenzamide Chemical compound C(C=C)(=O)N1CCN(CC1)C1=NC=NC2=CC(=C(C=C12)Cl)C1=C(C(=O)N)C=CC=C1F AYCKHIMPCUTHOI-UHFFFAOYSA-N 0.000 claims 1
- MOFVIXHUPWXSOT-UHFFFAOYSA-N 2-[6-chloro-4-(4-prop-2-enoylpiperazin-1-yl)quinazolin-7-yl]-4-fluorobenzamide Chemical compound C(C=C)(=O)N1CCN(CC1)C1=NC=NC2=CC(=C(C=C12)Cl)C1=C(C(=O)N)C=CC(=C1)F MOFVIXHUPWXSOT-UHFFFAOYSA-N 0.000 claims 1
- TXUHBVSABGFSLY-UHFFFAOYSA-N 2-[6-chloro-4-(4-prop-2-enoylpiperazin-1-yl)quinazolin-7-yl]-5-fluorobenzamide Chemical compound C(C=C)(=O)N1CCN(CC1)C1=NC=NC2=CC(=C(C=C12)Cl)C1=C(C(=O)N)C=C(C=C1)F TXUHBVSABGFSLY-UHFFFAOYSA-N 0.000 claims 1
- OEYRXRCUFNXZKZ-UHFFFAOYSA-N 2-[7-chloro-4-(4-prop-2-enoylpiperazin-1-yl)quinazolin-6-yl]benzonitrile Chemical compound ClC1=C(C=C2C(=C1)N=CN=C2N1CCN(CC1)C(=O)C=C)C1=C(C=CC=C1)C#N OEYRXRCUFNXZKZ-UHFFFAOYSA-N 0.000 claims 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 1
- JWAZRIHNYRIHIV-UHFFFAOYSA-N 2-naphthol Chemical compound C1=CC=CC2=CC(O)=CC=C21 JWAZRIHNYRIHIV-UHFFFAOYSA-N 0.000 claims 1
- YBMGETHIZZIDAY-UHFFFAOYSA-N 3-[6-chloro-4-(4-prop-2-enoylpiperazin-1-yl)quinazolin-7-yl]-1H-pyridin-2-one Chemical compound C(C=C)(=O)N1CCN(CC1)C1=NC=NC2=CC(=C(C=C12)Cl)C=1C(NC=CC=1)=O YBMGETHIZZIDAY-UHFFFAOYSA-N 0.000 claims 1
- XZPJSAZLBFIPCP-UHFFFAOYSA-N 3-[6-chloro-4-(4-prop-2-enoylpiperazin-1-yl)quinazolin-7-yl]-2-fluoro-N,N-dimethylbenzamide Chemical compound C(C=C)(=O)N1CCN(CC1)C1=NC=NC2=CC(=C(C=C12)Cl)C=1C(=C(C(=O)N(C)C)C=CC=1)F XZPJSAZLBFIPCP-UHFFFAOYSA-N 0.000 claims 1
- BHFZNIORCYUIJN-UHFFFAOYSA-N 3-[6-chloro-4-(4-prop-2-enoylpiperazin-1-yl)quinazolin-7-yl]-4-fluorobenzamide Chemical compound C(C=C)(=O)N1CCN(CC1)C1=NC=NC2=CC(=C(C=C12)Cl)C=1C=C(C(=O)N)C=CC=1F BHFZNIORCYUIJN-UHFFFAOYSA-N 0.000 claims 1
- FEORHTOGMHDMJB-UHFFFAOYSA-N 3-[6-chloro-4-(4-prop-2-enoylpiperazin-1-yl)quinazolin-7-yl]benzonitrile Chemical compound C(C=C)(=O)N1CCN(CC1)C1=NC=NC2=CC(=C(C=C12)Cl)C=1C=C(C#N)C=CC=1 FEORHTOGMHDMJB-UHFFFAOYSA-N 0.000 claims 1
- FWOPJXVQGMZKEP-UHFFFAOYSA-N 3-methyl-2h-indazole Chemical compound C1=CC=CC2=C(C)NN=C21 FWOPJXVQGMZKEP-UHFFFAOYSA-N 0.000 claims 1
- YFRRPYCNBGGWIN-UHFFFAOYSA-N 4-(6-bromo-7-chloroquinazolin-4-yl)-1-prop-2-enoylpiperazine-2-carbonitrile Chemical compound C(C=C)(=O)N1C(CN(CC1)C1=NC=NC2=CC(=C(C=C12)Br)Cl)C#N YFRRPYCNBGGWIN-UHFFFAOYSA-N 0.000 claims 1
- RUNKODQBPBTQDU-UHFFFAOYSA-N 4-(6-chloroisoquinolin-1-yl)-1-prop-2-enoylpiperazine-2-carbonitrile Chemical compound Clc1ccc2c(nccc2c1)N1CCN(C(C1)C#N)C(=O)C=C RUNKODQBPBTQDU-UHFFFAOYSA-N 0.000 claims 1
- BMXASPNZGJNNQC-UHFFFAOYSA-N 4-(7-chloro-6-cyclopropylquinazolin-4-yl)-1-prop-2-enoylpiperazine-2-carbonitrile Chemical compound Clc1cc2ncnc(N3CCN(C(C3)C#N)C(=O)C=C)c2cc1C1CC1 BMXASPNZGJNNQC-UHFFFAOYSA-N 0.000 claims 1
- GUTURVWWHABZHG-UHFFFAOYSA-N 4-(7-chloro-6-phenylquinazolin-4-yl)-1-prop-2-enoylpiperazine-2-carbonitrile Chemical compound C(C=C)(=O)N1C(CN(CC1)C1=NC=NC2=CC(=C(C=C12)C1=CC=CC=C1)Cl)C#N GUTURVWWHABZHG-UHFFFAOYSA-N 0.000 claims 1
- BALSYFMHNYIXPE-UHFFFAOYSA-N 4-(7-chloro-6-thiophen-2-ylquinazolin-4-yl)-1-prop-2-enoylpiperazine-2-carbonitrile Chemical compound C(C=C)(=O)N1C(CN(CC1)C1=NC=NC2=CC(=C(C=C12)C=1SC=CC=1)Cl)C#N BALSYFMHNYIXPE-UHFFFAOYSA-N 0.000 claims 1
- YCENLHYJVFJRFQ-UHFFFAOYSA-N 4-(7-chloroquinazolin-4-yl)-1-prop-2-enoylpiperazine-2-carbonitrile Chemical compound C(C=C)(=O)N1C(CN(CC1)C1=NC=NC2=CC(=CC=C12)Cl)C#N YCENLHYJVFJRFQ-UHFFFAOYSA-N 0.000 claims 1
- WDSRBSCRAAMXJM-UHFFFAOYSA-N 4-[6-chloro-4-(4-prop-2-enoylpiperazin-1-yl)quinazolin-7-yl]-1,3-dihydroindol-2-one Chemical compound C(C=C)(=O)N1CCN(CC1)C1=NC=NC2=CC(=C(C=C12)Cl)C1=C2CC(NC2=CC=C1)=O WDSRBSCRAAMXJM-UHFFFAOYSA-N 0.000 claims 1
- URZDPZUKASTBEH-UHFFFAOYSA-N 4-[6-chloro-7-(2-hydroxyphenyl)quinazolin-4-yl]-1-prop-2-enoylpiperazine-2-carbonitrile Chemical compound C(C=C)(=O)N1C(CN(CC1)C1=NC=NC2=CC(=C(C=C12)Cl)C1=C(C=CC=C1)O)C#N URZDPZUKASTBEH-UHFFFAOYSA-N 0.000 claims 1
- LNFFCAOMIHCZSQ-UHFFFAOYSA-N 4-[7-chloro-4-(4-prop-2-enoylpiperazin-1-yl)quinazolin-6-yl]benzonitrile Chemical compound C(C=C)(=O)N1CCN(CC1)C1=NC=NC2=CC(=C(C=C12)C1=CC=C(C#N)C=C1)Cl LNFFCAOMIHCZSQ-UHFFFAOYSA-N 0.000 claims 1
- JIIBSIMXAXZDEL-UHFFFAOYSA-N 4-[7-chloro-6-(4-chlorophenyl)quinazolin-4-yl]-1-prop-2-enoylpiperazine-2-carbonitrile Chemical compound Clc1ccc(cc1)-c1cc2c(ncnc2cc1Cl)N1CCN(C(C1)C#N)C(=O)C=C JIIBSIMXAXZDEL-UHFFFAOYSA-N 0.000 claims 1
- VFWDUIQHGFCQCC-UHFFFAOYSA-N 4-chloro-1-[6-chloro-4-(4-prop-2-enoylpiperazin-1-yl)quinazolin-7-yl]pyridin-2-one Chemical compound C(C=C)(=O)N1CCN(CC1)C1=NC=NC2=CC(=C(C=C12)Cl)N1C(C=C(C=C1)Cl)=O VFWDUIQHGFCQCC-UHFFFAOYSA-N 0.000 claims 1
- ALSOZZIBQRTXJW-UHFFFAOYSA-N 5-chloro-1-[6-chloro-4-(4-prop-2-enoylpiperazin-1-yl)quinazolin-7-yl]pyridin-2-one Chemical compound Clc1ccc(=O)n(c1)-c1cc2ncnc(N3CCN(CC3)C(=O)C=C)c2cc1Cl ALSOZZIBQRTXJW-UHFFFAOYSA-N 0.000 claims 1
- KSYCXNAFPJVWGI-UHFFFAOYSA-N 6-chloro-4-(4-prop-2-enoylpiperazin-1-yl)-7-[2-(trifluoromethyl)phenyl]quinoline-3-carbonitrile Chemical compound C(C=C)(=O)N1CCN(CC1)C1=C(C=NC2=CC(=C(C=C12)Cl)C1=C(C=CC=C1)C(F)(F)F)C#N KSYCXNAFPJVWGI-UHFFFAOYSA-N 0.000 claims 1
- AFZFGUVAZBYPEZ-VMPITWQZSA-N 6-chloro-4-[4-[(E)-4-(dimethylamino)but-2-enoyl]piperazin-1-yl]-8-fluoro-7-(3-hydroxynaphthalen-1-yl)quinoline-3-carbonitrile Chemical compound ClC=1C=C2C(=C(C=NC2=C(C=1C1=CC(=CC2=CC=CC=C12)O)F)C#N)N1CCN(CC1)C(\C=C\CN(C)C)=O AFZFGUVAZBYPEZ-VMPITWQZSA-N 0.000 claims 1
- SYSYFCOOZJVCME-UHFFFAOYSA-N 6-chloro-7-(2,4-difluorophenyl)-4-(4-prop-2-enoylpiperazin-1-yl)quinoline-3-carbonitrile Chemical compound C(C=C)(=O)N1CCN(CC1)C1=C(C=NC2=CC(=C(C=C12)Cl)C1=C(C=C(C=C1)F)F)C#N SYSYFCOOZJVCME-UHFFFAOYSA-N 0.000 claims 1
- FUWLOSODTFHBHF-UHFFFAOYSA-N 6-chloro-7-(2-fluoro-5-hydroxyphenyl)-4-(4-prop-2-enoylpiperazin-1-yl)quinoline-3-carbonitrile Chemical compound C(C=C)(=O)N1CCN(CC1)C1=C(C=NC2=CC(=C(C=C12)Cl)C1=C(C=CC(=C1)O)F)C#N FUWLOSODTFHBHF-UHFFFAOYSA-N 0.000 claims 1
- JMJQHWIEHAOQSF-UHFFFAOYSA-N 6-chloro-7-(2-fluorophenyl)-4-(4-prop-2-enoylpiperazin-1-yl)quinoline-3-carbonitrile Chemical compound FC1=CC=CC=C1C1=C(Cl)C=C2C(=C1)N=CC(C#N)=C2N1CCN(CC1)C(=O)C=C JMJQHWIEHAOQSF-UHFFFAOYSA-N 0.000 claims 1
- BQKNNURHWKWWQE-UHFFFAOYSA-N 6-chloro-7-(2-hydroxynaphthalen-1-yl)-4-(4-prop-2-enoylpiperazin-1-yl)quinoline-3-carbonitrile Chemical compound C(C=C)(=O)N1CCN(CC1)C1=C(C=NC2=CC(=C(C=C12)Cl)C1=C(C=CC2=CC=CC=C12)O)C#N BQKNNURHWKWWQE-UHFFFAOYSA-N 0.000 claims 1
- BPSLWCGTKVZQNA-UHFFFAOYSA-N 6-chloro-7-(2-hydroxyphenyl)-4-(4-prop-2-enoylpiperazin-1-yl)quinoline-3-carbonitrile Chemical compound C(C=C)(=O)N1CCN(CC1)C1=C(C=NC2=CC(=C(C=C12)Cl)C1=C(C=CC=C1)O)C#N BPSLWCGTKVZQNA-UHFFFAOYSA-N 0.000 claims 1
- QJHUWZSJXFIMQD-UHFFFAOYSA-N 6-chloro-7-naphthalen-1-yl-4-(4-prop-2-enoylpiperazin-1-yl)quinoline-3-carbonitrile Chemical compound C(C=C)(=O)N1CCN(CC1)C1=C(C=NC2=CC(=C(C=C12)Cl)C1=CC=CC2=CC=CC=C12)C#N QJHUWZSJXFIMQD-UHFFFAOYSA-N 0.000 claims 1
- MZYMZAOOTFYHBO-UHFFFAOYSA-N 6-chloro-8-fluoro-4-(4-prop-2-enoylpiperazin-1-yl)-7-[2-(trifluoromethyl)phenyl]quinoline-3-carbonitrile Chemical compound C(C=C)(=O)N1CCN(CC1)C1=C(C=NC2=C(C(=C(C=C12)Cl)C1=C(C=CC=C1)C(F)(F)F)F)C#N MZYMZAOOTFYHBO-UHFFFAOYSA-N 0.000 claims 1
- QHPMKPFWCVZEQT-UHFFFAOYSA-N 6-chloro-8-fluoro-7-(2-fluorophenyl)-4-(4-prop-2-enoylpiperazin-1-yl)quinoline-3-carbonitrile Chemical compound C(C=C)(=O)N1CCN(CC1)C1=C(C=NC2=C(C(=C(C=C12)Cl)C1=C(C=CC=C1)F)F)C#N QHPMKPFWCVZEQT-UHFFFAOYSA-N 0.000 claims 1
- MURTXXKMDMYPGX-UHFFFAOYSA-N 6-chloro-8-fluoro-7-(2-hydroxynaphthalen-1-yl)-4-(4-prop-2-enoylpiperazin-1-yl)quinoline-3-carbonitrile Chemical compound C(C=C)(=O)N1CCN(CC1)C1=C(C=NC2=C(C(=C(C=C12)Cl)C1=C(C=CC2=CC=CC=C12)O)F)C#N MURTXXKMDMYPGX-UHFFFAOYSA-N 0.000 claims 1
- FOUMXRPICAFSOF-UHFFFAOYSA-N 6-chloro-8-fluoro-7-(3-hydroxynaphthalen-1-yl)-4-(4-prop-2-enoylpiperazin-1-yl)quinazoline-2-carbonitrile Chemical compound Oc1cc(-c2c(Cl)cc3c(nc(nc3c2F)C#N)N2CCN(CC2)C(=O)C=C)c2ccccc2c1 FOUMXRPICAFSOF-UHFFFAOYSA-N 0.000 claims 1
- XGPQIZWCDCOEFA-UHFFFAOYSA-N 6-chloro-8-fluoro-7-(3-hydroxynaphthalen-1-yl)-4-(4-prop-2-enoylpiperazin-1-yl)quinoline-3-carbonitrile Chemical compound C(C=C)(=O)N1CCN(CC1)C1=C(C=NC2=C(C(=C(C=C12)Cl)C1=CC(=CC2=CC=CC=C12)O)F)C#N XGPQIZWCDCOEFA-UHFFFAOYSA-N 0.000 claims 1
- LWVFMOZSMLVQQW-UHFFFAOYSA-N 6-chloro-8-fluoro-7-(5-methyl-1H-indazol-4-yl)-4-(3-methyl-4-prop-2-enoylpiperazin-1-yl)quinoline-3-carbonitrile Chemical compound C(C=C)(=O)N1C(CN(CC1)C1=C(C=NC2=C(C(=C(C=C12)Cl)C1=C2C=NNC2=CC=C1C)F)C#N)C LWVFMOZSMLVQQW-UHFFFAOYSA-N 0.000 claims 1
- LAHYQIYHLLKGOK-UHFFFAOYSA-N 6-chloro-8-fluoro-7-(5-methyl-1H-indazol-4-yl)-4-(4-prop-2-enoylpiperazin-1-yl)quinoline-3-carbonitrile Chemical compound C(C=C)(=O)N1CCN(CC1)C1=C(C=NC2=C(C(=C(C=C12)Cl)C1=C2C=NNC2=CC=C1C)F)C#N LAHYQIYHLLKGOK-UHFFFAOYSA-N 0.000 claims 1
- KSUVZAZSFKTSOT-UHFFFAOYSA-N 6-chloro-8-fluoro-7-(6-methyl-1H-indazol-7-yl)-4-(4-prop-2-enoylpiperazin-1-yl)quinoline-3-carbonitrile Chemical compound C(C=C)(=O)N1CCN(CC1)C1=C(C=NC2=C(C(=C(C=C12)Cl)C=1C(=CC=C2C=NNC=12)C)F)C#N KSUVZAZSFKTSOT-UHFFFAOYSA-N 0.000 claims 1
- ZSWSOVPABXFQPU-UHFFFAOYSA-N 7-(2-fluorophenyl)-4-(4-prop-2-enoylpiperazin-1-yl)quinazoline-6-carbonitrile Chemical compound C(C=C)(=O)N1CCN(CC1)C1=NC=NC2=CC(=C(C=C12)C#N)C1=C(C=CC=C1)F ZSWSOVPABXFQPU-UHFFFAOYSA-N 0.000 claims 1
- QOFYCVARXOINFK-UHFFFAOYSA-N 7-chloro-4-(3-cyano-4-prop-2-enoylpiperazin-1-yl)quinazoline-6-carbonitrile Chemical compound Clc1cc2ncnc(N3CCN(C(C3)C#N)C(=O)C=C)c2cc1C#N QOFYCVARXOINFK-UHFFFAOYSA-N 0.000 claims 1
- OKGVORORUZXCBC-UHFFFAOYSA-N 7-chloro-6-(2,4-difluorophenyl)-1-(1-prop-2-enoylpiperidin-4-yl)quinoxalin-2-one Chemical compound Fc1ccc(c(F)c1)-c1cc2ncc(=O)n(C3CCN(CC3)C(=O)C=C)c2cc1Cl OKGVORORUZXCBC-UHFFFAOYSA-N 0.000 claims 1
- VUXXXBJEMCUMER-UHFFFAOYSA-N 7-chloro-6-(4-chlorophenyl)-4-(4-ethenylsulfonylpiperazin-1-yl)quinazoline Chemical compound Clc1ccc(cc1)-c1cc2c(ncnc2cc1Cl)N1CCN(CC1)S(=O)(=O)C=C VUXXXBJEMCUMER-UHFFFAOYSA-N 0.000 claims 1
- PBIAALISGKFZKF-UHFFFAOYSA-N 7-chloro-6-(4-chlorophenyl)-4-(4-prop-2-enoylpiperazin-1-yl)quinoline-3-carbonitrile Chemical compound Clc1ccc(cc1)-c1cc2c(N3CCN(CC3)C(=O)C=C)c(cnc2cc1Cl)C#N PBIAALISGKFZKF-UHFFFAOYSA-N 0.000 claims 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 1
- 241000975394 Evechinus chloroticus Species 0.000 claims 1
- UNUZYLQBNYXVFL-UHFFFAOYSA-N N-[1-(6-chloro-7-phenylquinazolin-4-yl)piperidin-4-yl]prop-2-enamide Chemical compound ClC=1C=C2C(=NC=NC2=CC=1C1=CC=CC=C1)N1CCC(CC1)NC(C=C)=O UNUZYLQBNYXVFL-UHFFFAOYSA-N 0.000 claims 1
- CEILIMZRNOROED-UHFFFAOYSA-N N-[1-[7-chloro-6-(2-chlorophenyl)quinazolin-4-yl]azetidin-3-yl]prop-2-enamide Chemical compound ClC1=C(C=C2C(=NC=NC2=C1)N1CC(C1)NC(C=C)=O)C1=C(C=CC=C1)Cl CEILIMZRNOROED-UHFFFAOYSA-N 0.000 claims 1
- MNHCDQAHJAMWHG-UHFFFAOYSA-N N-[3-[6-chloro-4-(4-prop-2-enoylpiperazin-1-yl)quinazolin-7-yl]-4-fluorophenyl]acetamide Chemical compound C(C=C)(=O)N1CCN(CC1)C1=NC=NC2=CC(=C(C=C12)Cl)C=1C=C(C=CC=1F)NC(C)=O MNHCDQAHJAMWHG-UHFFFAOYSA-N 0.000 claims 1
- WLAJLBBYHKTRIU-UHFFFAOYSA-N N-[4-[6-chloro-4-(4-prop-2-enoylpiperazin-1-yl)quinazolin-7-yl]-5-methylpyrimidin-2-yl]prop-2-enamide Chemical compound C(C=C)(=O)N1CCN(CC1)C1=NC=NC2=CC(=C(C=C12)Cl)C1=NC(=NC=C1C)NC(C=C)=O WLAJLBBYHKTRIU-UHFFFAOYSA-N 0.000 claims 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 1
- AIMMVWOEOZMVMS-UHFFFAOYSA-N cyclopropanecarboxamide Chemical compound NC(=O)C1CC1 AIMMVWOEOZMVMS-UHFFFAOYSA-N 0.000 claims 1
- LWMDZEGKAFJEBE-AATRIKPKSA-N ethyl (E)-4-[4-[6-chloro-7-(2,4-difluorophenyl)quinazolin-4-yl]piperazin-1-yl]-4-oxobut-2-enoate Chemical compound ClC=1C=C2C(=NC=NC2=CC=1C1=C(C=C(C=C1)F)F)N1CCN(CC1)C(/C=C/C(=O)OCC)=O LWMDZEGKAFJEBE-AATRIKPKSA-N 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 claims 1
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 1
- 230000035772 mutation Effects 0.000 description 8
- 102200124918 rs121913250 Human genes 0.000 description 8
- 102100029974 GTPase HRas Human genes 0.000 description 7
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 description 7
- 102100030708 GTPase KRas Human genes 0.000 description 6
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 6
- 125000006728 (C1-C6) alkynyl group Chemical group 0.000 description 4
- 102200006538 rs121913530 Human genes 0.000 description 4
- 244000007835 Cyamopsis tetragonoloba Species 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 102000008300 Mutant Proteins Human genes 0.000 description 2
- 108010021466 Mutant Proteins Proteins 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 208000015768 polyposis Diseases 0.000 description 2
- 102200006614 rs104894229 Human genes 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- HOSGXJWQVBHGLT-UHFFFAOYSA-N 6-hydroxy-3,4-dihydro-1h-quinolin-2-one Chemical group N1C(=O)CCC2=CC(O)=CC=C21 HOSGXJWQVBHGLT-UHFFFAOYSA-N 0.000 description 1
- 102100039788 GTPase NRas Human genes 0.000 description 1
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical group [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361889460P | 2013-10-10 | 2013-10-10 | |
| US61/889,460 | 2013-10-10 | ||
| US201462034619P | 2014-08-07 | 2014-08-07 | |
| US62/034,619 | 2014-08-07 | ||
| US201462052366P | 2014-09-18 | 2014-09-18 | |
| US62/052,366 | 2014-09-18 | ||
| TW103135318 | 2014-10-09 | ||
| JO289/2014 | 2014-10-09 | ||
| JOP/2014/0289A JO3805B1 (ar) | 2013-10-10 | 2014-10-09 | مثبطات كراس جي12سي |
| TW103135318A TWI659021B (zh) | 2013-10-10 | 2014-10-09 | Kras g12c之抑制劑 |
| PCT/US2014/060036 WO2015054572A1 (en) | 2013-10-10 | 2014-10-10 | Inhibitors of kras g12c |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016532656A JP2016532656A (ja) | 2016-10-20 |
| JP2016532656A5 true JP2016532656A5 (https=) | 2017-11-09 |
| JP6559123B2 JP6559123B2 (ja) | 2019-08-14 |
Family
ID=61800013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016521333A Active JP6559123B2 (ja) | 2013-10-10 | 2014-10-10 | Krasg12cの阻害剤 |
Country Status (17)
| Country | Link |
|---|---|
| EP (2) | EP3055290B1 (https=) |
| JP (1) | JP6559123B2 (https=) |
| KR (1) | KR20160076519A (https=) |
| CN (1) | CN106488910B (https=) |
| AU (1) | AU2014331794C1 (https=) |
| BR (1) | BR112016008016B8 (https=) |
| CA (1) | CA2926328C (https=) |
| EA (1) | EA033689B9 (https=) |
| IL (1) | IL244699B (https=) |
| MX (1) | MX380928B (https=) |
| NI (1) | NI201600049A (https=) |
| NO (1) | NO20160646A1 (https=) |
| PH (1) | PH12016500538B1 (https=) |
| SG (1) | SG11201602662YA (https=) |
| UA (1) | UA119971C2 (https=) |
| WO (1) | WO2015054572A1 (https=) |
| ZA (1) | ZA201602245B (https=) |
Families Citing this family (262)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2836482B1 (en) | 2012-04-10 | 2019-12-25 | The Regents of The University of California | Compositions and methods for treating cancer |
| MX394360B (es) | 2013-03-14 | 2025-03-24 | Sumitomo Pharma Oncology Inc | Inhibidores de jak2 y alk2 y metodos para su uso. |
| US9745319B2 (en) | 2013-03-15 | 2017-08-29 | Araxes Pharma Llc | Irreversible covalent inhibitors of the GTPase K-Ras G12C |
| US9227978B2 (en) | 2013-03-15 | 2016-01-05 | Araxes Pharma Llc | Covalent inhibitors of Kras G12C |
| JO3805B1 (ar) * | 2013-10-10 | 2021-01-31 | Araxes Pharma Llc | مثبطات كراس جي12سي |
| JO3556B1 (ar) * | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| WO2016049568A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Methods and compositions for inhibition of ras |
| JP2017528498A (ja) * | 2014-09-25 | 2017-09-28 | アラクセス ファーマ エルエルシー | Kras g12c変異体タンパク質のインヒビター |
| CN105712998B (zh) * | 2014-12-05 | 2019-12-13 | 上海润诺生物科技有限公司 | 氮杂吲哚类衍生物、其制备方法及其在医药上的应用 |
| ES2898765T3 (es) | 2015-04-10 | 2022-03-08 | Araxes Pharma Llc | Compuestos de quinazolina sustituidos y métodos de uso de los mismos |
| US10428064B2 (en) | 2015-04-15 | 2019-10-01 | Araxes Pharma Llc | Fused-tricyclic inhibitors of KRAS and methods of use thereof |
| WO2017015562A1 (en) * | 2015-07-22 | 2017-01-26 | Araxes Pharma Llc | Substituted quinazoline compounds and their use as inhibitors of g12c mutant kras, hras and/or nras proteins |
| CN108026046B (zh) * | 2015-07-22 | 2021-12-21 | 亚瑞克西斯制药公司 | 取代的喹唑啉化合物及其作为g12c突变体kras、hras和/或nras蛋白质的抑制剂的用途 |
| US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| EP3330271B1 (en) | 2015-07-31 | 2022-09-07 | Taiho Pharmaceutical Co., Ltd. | PYRROLO[2,3-d]PYRIMIDINE COMPOUND OR SALT THEREOF |
| EP3356347A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| WO2017058728A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| WO2017058902A1 (en) * | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| EP3356349A1 (en) * | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| EP3356359B1 (en) | 2015-09-28 | 2021-10-20 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| EP3356351A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| KR102678538B1 (ko) * | 2015-10-02 | 2024-06-28 | 센티넬 온콜로지 리미티드 | P70s6 키나제 억제제로서의 2-아미노퀴나졸린 유도체 |
| WO2017070256A2 (en) | 2015-10-19 | 2017-04-27 | Araxes Pharma Llc | Method for screening inhibitors of ras |
| KR20180081596A (ko) * | 2015-11-16 | 2018-07-16 | 아락세스 파마 엘엘씨 | 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법 |
| US9988357B2 (en) | 2015-12-09 | 2018-06-05 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
| SG11201804901WA (en) | 2015-12-22 | 2018-07-30 | SHY Therapeutics LLC | Compounds for the treatment of cancer and inflammatory disease |
| WO2017172979A1 (en) | 2016-03-30 | 2017-10-05 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| KR102444509B1 (ko) * | 2016-05-18 | 2022-09-19 | 미라티 테라퓨틱스, 인크. | Kras g12c 억제제 |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| WO2018064510A1 (en) * | 2016-09-29 | 2018-04-05 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| EP3523289A1 (en) | 2016-10-07 | 2019-08-14 | Araxes Pharma LLC | Heterocyclic compounds as inhibitors of ras and methods of use thereof |
| KR20190095355A (ko) | 2016-12-15 | 2019-08-14 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 암의 치료를 위한 조성물 및 방법 |
| CN110366550A (zh) * | 2016-12-22 | 2019-10-22 | 美国安进公司 | 作为用于治疗肺癌、胰腺癌或结直肠癌的KRAS G12C抑制剂的苯并异噻唑、异噻唑并[3,4-b]吡啶、喹唑啉、酞嗪、吡啶并[2,3-d]哒嗪和吡啶并[2,3-d]嘧啶衍生物 |
| EP3573966A1 (en) * | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused n-heterocyclic compounds and methods of use thereof |
| US11136308B2 (en) * | 2017-01-26 | 2021-10-05 | Araxes Pharma Llc | Substituted quinazoline and quinazolinone compounds and methods of use thereof |
| JP7327802B2 (ja) * | 2017-01-26 | 2023-08-16 | アラクセス ファーマ エルエルシー | 縮合ヘテロ-ヘテロ二環式化合物およびその使用方法 |
| WO2018140599A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
| EP3573954A1 (en) * | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
| WO2018140513A1 (en) * | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
| JOP20190186A1 (ar) | 2017-02-02 | 2019-08-01 | Astellas Pharma Inc | مركب كينازولين |
| JP7161760B2 (ja) | 2017-02-03 | 2022-10-27 | 国立大学法人東北大学 | 複素環化合物 |
| WO2018172250A1 (en) | 2017-03-21 | 2018-09-27 | Bayer Pharma Aktiengesellschaft | 2-methyl-quinazolines |
| AU2018273356B2 (en) * | 2017-05-22 | 2021-09-16 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| CN110869357A (zh) * | 2017-05-25 | 2020-03-06 | 亚瑞克西斯制药公司 | 化合物及其用于治疗癌症的使用方法 |
| US10745385B2 (en) | 2017-05-25 | 2020-08-18 | Araxes Pharma Llc | Covalent inhibitors of KRAS |
| WO2018218069A1 (en) | 2017-05-25 | 2018-11-29 | Araxes Pharma Llc | Quinazoline derivatives as modulators of mutant kras, hras or nras |
| EA201992780A1 (ru) | 2017-06-21 | 2020-06-02 | ШАЙ ТЕРАПЬЮТИКС ЭлЭлСи | Соединения, которые взаимодействуют с суперсемейством ras, для лечения рака, воспалительных заболеваний, ras-опатий и фиброзного заболевания |
| CN107382742A (zh) * | 2017-07-30 | 2017-11-24 | 梁江丽 | 一种芳香含三氟甲基中间体5‑氯‑2‑氟‑4‑(三氟甲基)苯胺盐酸盐的合成新方法 |
| AU2018329920B2 (en) * | 2017-09-08 | 2022-12-01 | Amgen Inc. | Inhibitors of KRAS G12C and methods of using the same |
| LT3710439T (lt) * | 2017-11-15 | 2023-05-10 | Mirati Therapeutics, Inc. | Kras g12c inhibitoriai |
| US10647715B2 (en) | 2017-11-15 | 2020-05-12 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
| US10597405B2 (en) | 2017-12-08 | 2020-03-24 | Astrazeneca Ab | Chemical compounds |
| SMT202200396T1 (it) | 2017-12-13 | 2022-11-18 | Lupin Ltd | Composti eterociclici biciclici sostituiti come inibitori di prmt5 |
| EP3842433B1 (en) | 2018-01-19 | 2023-11-01 | Medshine Discovery Inc. | Pyridone-pyrimidine derivative acting as krasg12c mutein inhibitor |
| TW201942115A (zh) | 2018-02-01 | 2019-11-01 | 美商輝瑞股份有限公司 | 作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物 |
| EP3762379A1 (en) | 2018-03-07 | 2021-01-13 | Bayer Aktiengesellschaft | Identification and use of erk5 inhibitors |
| WO2019195609A2 (en) | 2018-04-04 | 2019-10-10 | Arvinas Operations, Inc. | Modulators of proteolysis and associated methods of use |
| KR20210003780A (ko) | 2018-04-05 | 2021-01-12 | 스미토모 다이니폰 파마 온콜로지, 인크. | Axl 키나제 억제제 및 그의 용도 |
| US20220274979A1 (en) | 2018-04-18 | 2022-09-01 | Bayer Pharma Aktiengesellschaft | 2-methyl-aza-quinazolines |
| EP3788053B1 (en) | 2018-05-04 | 2024-07-10 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| CA3098574A1 (en) * | 2018-05-04 | 2019-11-07 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| WO2019217307A1 (en) * | 2018-05-07 | 2019-11-14 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| TW202012415A (zh) * | 2018-05-08 | 2020-04-01 | 瑞典商阿斯特捷利康公司 | 化學化合物 |
| MA52564A (fr) * | 2018-05-10 | 2021-03-17 | Amgen Inc | Inhibiteurs de kras g12c pour le traitement du cancer |
| US11096939B2 (en) | 2018-06-01 | 2021-08-24 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| MX2020012204A (es) * | 2018-06-11 | 2021-03-31 | Amgen Inc | Inhibidores de kras g12c para tratar el cáncer. |
| US11285156B2 (en) | 2018-06-12 | 2022-03-29 | Amgen Inc. | Substituted piperazines as KRAS G12C inhibitors |
| AU2019310590A1 (en) | 2018-07-26 | 2021-01-14 | Sumitomo Pharma Oncology, Inc. | Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same |
| JP2021176819A (ja) * | 2018-07-31 | 2021-11-11 | アステラス製薬株式会社 | キナゾリン化合物を有効成分とする医薬組成物 |
| JP2021176820A (ja) * | 2018-07-31 | 2021-11-11 | アステラス製薬株式会社 | キナゾリン化合物を有効成分とする医薬組成物 |
| MX2021000887A (es) * | 2018-08-01 | 2021-03-31 | Araxes Pharma Llc | Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer. |
| AU2019320945C1 (en) | 2018-08-16 | 2021-09-30 | F. Hoffmann-La Roche Ag | Fused ring compounds |
| EP3849537B1 (en) | 2018-09-10 | 2024-10-23 | Mirati Therapeutics, Inc. | Combination therapies |
| EP3849535A4 (en) | 2018-09-10 | 2022-06-29 | Mirati Therapeutics, Inc. | Combination therapies |
| JP2022500385A (ja) | 2018-09-10 | 2022-01-04 | ミラティ セラピューティクス, インコーポレイテッド | 組み合わせ療法 |
| EA202190749A1 (ru) | 2018-09-10 | 2021-07-09 | Мирати Терапьютикс, Инк. | Способы комбинированной терапии |
| JP2022502495A (ja) | 2018-09-25 | 2022-01-11 | ブラック ダイアモンド セラピューティクス,インコーポレイティド | チロシンキナーゼ阻害剤としてのキナゾリン誘導体、組成物、それらの作製方法、およびそれらの使用 |
| EP3628664A1 (en) | 2018-09-25 | 2020-04-01 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Irreversible inhibitors of kras g12c mutant |
| CN109232259B (zh) * | 2018-09-27 | 2021-05-28 | 浙江理工大学 | 一种硝基苯乙酮的制备方法 |
| TW202033518A (zh) | 2018-10-15 | 2020-09-16 | 美商美國禮來大藥廠 | Kras g12c 抑制劑 |
| CN113207291A (zh) | 2018-10-24 | 2021-08-03 | 亚瑞克西斯制药公司 | 2-(2-丙烯酰基-2,6-二氮杂螺[3.4]辛-6-基)-6-(1h-吲唑-4-基)苄腈衍生物及相关化合物作为用于抑制肿瘤转移的g12c突变kras蛋白的抑制剂 |
| CN113226321B (zh) * | 2018-10-26 | 2024-12-17 | 阿利安制药有限责任公司 | 吡唑基化合物及其使用方法 |
| WO2020085504A1 (ja) | 2018-10-26 | 2020-04-30 | 大鵬薬品工業株式会社 | 光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法 |
| MX390349B (es) * | 2018-11-01 | 2025-03-20 | Centro De Investig Y De Estudios Avanzados Del I P N | Composiciones farmaceuticas para el tratamiento efectivo de cancer de pancreas. |
| MX394102B (es) * | 2018-11-01 | 2025-03-21 | Centro De Investig Y De Estudios Avanzados Del I P N | Composiciones farmaceuticas para el tratamiento efectivo de cancer colorectal. |
| PE20260440A1 (es) | 2018-11-09 | 2026-02-19 | Hoffmann La Roche | Compuestos de anillo fusionado |
| JP7516029B2 (ja) * | 2018-11-16 | 2024-07-16 | アムジエン・インコーポレーテツド | Kras g12c阻害剤化合物の重要な中間体の改良合成法 |
| AU2019384118B2 (en) | 2018-11-19 | 2025-06-12 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| EP3887373A1 (en) | 2018-11-29 | 2021-10-06 | Araxes Pharma LLC | Compounds and methods of use thereof for treatment of cancer |
| MX2021002804A (es) | 2018-12-05 | 2021-07-15 | Mirati Therapeutics Inc | Terapias de combinacion. |
| US12391705B2 (en) | 2018-12-19 | 2025-08-19 | Shy Therapeutics, Llc | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
| WO2020132384A1 (en) | 2018-12-21 | 2020-06-25 | Celgene Corporation | Thienopyridine inhibitors of ripk2 |
| EP3908283A4 (en) * | 2019-01-10 | 2022-10-12 | Mirati Therapeutics, Inc. | KRAS G12C INHIBITORS |
| EP3919483A4 (en) * | 2019-01-29 | 2022-02-09 | Brightgene Bio-medical Technology Co., Ltd. | HETEROCYCLIC BENZOPYRIDONE COMPOUND AND USE THEREOF |
| US20220152026A1 (en) | 2019-02-12 | 2022-05-19 | Novartis Ag | Pharmaceutical combination comprising tno155 and a krasg12c inhibitor |
| WO2020173935A1 (en) | 2019-02-26 | 2020-09-03 | Boehringer Ingelheim International Gmbh | New isoindolinone substituted indoles and derivatives as ras inhibitors |
| WO2020177629A1 (zh) * | 2019-03-01 | 2020-09-10 | 劲方医药科技(上海)有限公司 | 螺环取代的嘧啶并环类化合物,其制法与医药上的用途 |
| KR102934231B1 (ko) | 2019-03-05 | 2026-03-06 | 아스트라제네카 아베 | 항암제로 유용한 융합 삼환식 화합물 |
| CN111662232B (zh) * | 2019-03-06 | 2022-08-02 | 中国科学院上海药物研究所 | 具有2h-吲唑结构的小分子化合物及其合成和应用 |
| AU2020260629A1 (en) * | 2019-04-22 | 2021-12-09 | Betta Pharmaceuticals Co., Ltd | Quinazoline compound and pharmaceutical application thereof |
| EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
| JP7502337B2 (ja) * | 2019-05-20 | 2024-06-18 | カリフォルニア インスティチュート オブ テクノロジー | Kras g12cインヒビター及びその使用 |
| WO2020236947A1 (en) | 2019-05-21 | 2020-11-26 | Amgen Inc. | Solid state forms |
| AU2020277398B2 (en) | 2019-05-21 | 2026-01-29 | Amgen Inc. | Solid state forms |
| WO2020234103A1 (en) | 2019-05-21 | 2020-11-26 | Bayer Aktiengesellschaft | Identification and use of kras inhibitors |
| WO2020239077A1 (zh) * | 2019-05-29 | 2020-12-03 | 上海翰森生物医药科技有限公司 | 含氮杂环类衍生物调节剂、其制备方法和应用 |
| CN112552294B (zh) * | 2019-09-10 | 2023-12-19 | 上海翰森生物医药科技有限公司 | 含哌嗪杂环类衍生物抑制剂、其制备方法和应用 |
| CN112047948B (zh) * | 2019-06-06 | 2022-08-16 | 山东轩竹医药科技有限公司 | Kras突变体抑制剂 |
| HUE064493T2 (hu) | 2019-06-10 | 2024-03-28 | Lupin Ltd | PRMT5 inhibitorok |
| US12421236B2 (en) | 2019-06-25 | 2025-09-23 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Seven-membered heterocyclic derivative acting as KRAS G12C mutant protein inhibitor |
| CN112300173B (zh) * | 2019-07-30 | 2021-10-01 | 上海凌达生物医药有限公司 | 一类含氮多环类化合物、制备方法和用途 |
| CA3150681A1 (en) | 2019-08-14 | 2021-02-18 | Incyte Corporation | Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors |
| AU2020328598A1 (en) | 2019-08-15 | 2022-03-03 | Black Diamond Therapeutics, Inc. | Alkynyl quinazoline compounds |
| MX2022002465A (es) | 2019-08-29 | 2022-05-19 | Mirati Therapeutics Inc | Inhibidores de kras g12d. |
| KR102176937B1 (ko) * | 2019-09-11 | 2020-11-10 | 연세대학교 산학협력단 | 바이페린 억제제를 유효성분으로 포함하는 대사질환의 예방 또는 치료용 조성물 |
| KR102152974B1 (ko) * | 2019-09-11 | 2020-09-07 | 연세대학교 산학협력단 | 바이페린 억제제를 유효성분으로 포함하는 생체 내 열생성 증진용 조성물 |
| US20220402916A1 (en) * | 2019-09-18 | 2022-12-22 | Merck Sharp & Dohme Corp. | Small molecule inhibitors of kras g12c mutant |
| US12122787B2 (en) | 2019-09-20 | 2024-10-22 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Fused pyridone compound, and preparation method therefor and use thereof |
| WO2021052499A1 (zh) * | 2019-09-20 | 2021-03-25 | 上海济煜医药科技有限公司 | 稠合吡啶酮类化合物及其制备方法和应用 |
| WO2021061749A1 (en) | 2019-09-24 | 2021-04-01 | Mirati Therapeutics, Inc. | Combination therapies |
| WO2021063346A1 (zh) * | 2019-09-30 | 2021-04-08 | 上海迪诺医药科技有限公司 | Kras g12c抑制剂及其应用 |
| US11851426B2 (en) | 2019-10-11 | 2023-12-26 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| BR112022007680A2 (pt) * | 2019-10-25 | 2022-08-09 | Merck Sharp & Dohme | Derivados de n-(heteroaril)quinazolin-2-amina como inibidores de lrrk2, composições farmacêuticas, e usos dos mesmos |
| CN112225734B (zh) * | 2019-10-25 | 2021-12-07 | 南京瑞捷医药科技有限公司 | Kras g12c抑制剂及其用途 |
| UA129778C2 (uk) | 2019-10-28 | 2025-07-30 | Мерк Шарп Енд Доум Елелсі | Низькомолекулярні інгібітори g12c-мутантного kras |
| JP7601869B2 (ja) | 2019-10-30 | 2024-12-17 | ▲勁▼方医▲薬▼科技(上海)有限公司 | 置換された複素環-環系化合物、その調製方法及び医薬への応用 |
| US20230023023A1 (en) | 2019-10-31 | 2023-01-26 | Taiho Pharmaceutical Co., Ltd. | 4-aminobut-2-enamide derivatives and salts thereof |
| CN112778284B (zh) * | 2019-11-01 | 2022-04-05 | 四川海思科制药有限公司 | 一种嘧啶并环衍生物及其在医药上的应用 |
| AU2020372700A1 (en) | 2019-11-01 | 2022-05-12 | Syngenta Crop Protection Ag | Pesticidally active fused bicyclic heteroaromatic compounds |
| AU2020377925A1 (en) | 2019-11-04 | 2022-05-05 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202132316A (zh) | 2019-11-04 | 2021-09-01 | 美商銳新醫藥公司 | Ras抑制劑 |
| IL322454A (en) | 2019-11-04 | 2025-09-01 | Revolution Medicines Inc | ras inhibitors |
| EP4065231A1 (en) * | 2019-11-27 | 2022-10-05 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| CN111377918B (zh) * | 2019-11-29 | 2021-03-02 | 苏州信诺维医药科技有限公司 | 一种kras抑制剂化合物 |
| WO2021106231A1 (en) * | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
| EP4067343A4 (en) | 2019-11-29 | 2024-01-03 | Taiho Pharmaceutical Co., Ltd. | NEW PHENOLIC COMPOUND OR SALT THEREOF |
| CN113024544B (zh) * | 2019-12-09 | 2024-07-02 | 武汉誉祥医药科技有限公司 | 一种含氰基并杂环化合物及其用途 |
| PT3886991T (pt) * | 2019-12-11 | 2022-10-17 | Lilly Co Eli | Inibidores de kras g12c |
| PH12022551513A1 (en) | 2019-12-20 | 2023-04-24 | Mirati Therapeutics Inc | Sos1 inhibitors |
| WO2021120890A1 (en) | 2019-12-20 | 2021-06-24 | Novartis Ag | Pyrazolyl derivatives useful as anti-cancer agents |
| CN113061132B (zh) * | 2020-01-01 | 2023-11-14 | 上海凌达生物医药有限公司 | 一类稠环内酰胺类化合物、制备方法和用途 |
| CN113135924B (zh) * | 2020-01-19 | 2024-04-26 | 广东东阳光药业股份有限公司 | 嘧啶衍生物及其在药物中的应用 |
| GB202001344D0 (en) | 2020-01-31 | 2020-03-18 | Redx Pharma Plc | Ras Inhibitors |
| CN112159405B (zh) * | 2020-02-04 | 2021-09-14 | 广州必贝特医药技术有限公司 | 吡啶并嘧啶酮类化合物及其应用 |
| US20230150978A1 (en) | 2020-03-30 | 2023-05-18 | Enyo Pharma | Quinazolinone derivatives and uses thereof for treating a cancer |
| WO2021215545A1 (en) | 2020-04-24 | 2021-10-28 | Taiho Pharmaceutical Co., Ltd. | Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c |
| CA3177261A1 (en) * | 2020-04-29 | 2021-11-04 | Shanghai Ringene Biopharma Co., Ltd. | Benzothiazolyl biaryl compound, and preparation method and use |
| JP7808058B2 (ja) * | 2020-06-02 | 2026-01-28 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | がんを治療するための縮合環化2-アミノ-3-シアノチオフェン及び誘導体 |
| TW202210633A (zh) | 2020-06-05 | 2022-03-16 | 法商昂席歐公司 | 用於治療癌症之dbait分子與kras抑制劑的組合 |
| IL299131A (en) | 2020-06-18 | 2023-02-01 | Revolution Medicines Inc | Methods for delaying, preventing and treating acquired resistance to RAS inhibitors |
| WO2022002102A1 (en) * | 2020-06-30 | 2022-01-06 | InventisBio Co., Ltd. | Quinazoline compounds, preparation methods and uses thereof |
| CN113880827B (zh) * | 2020-07-03 | 2024-10-01 | 苏州闻天医药科技有限公司 | 一种用于抑制krasg12c突变蛋白的化合物及其制备方法和用途 |
| CN113929676A (zh) * | 2020-07-14 | 2022-01-14 | 浙江海正药业股份有限公司 | 吡啶并杂环类衍生物及其制备方法和用途 |
| JP7584815B2 (ja) * | 2020-08-02 | 2024-11-18 | 上▲海▼▲哲▼▲イェ▼生物科技有限公司 | 抗腫瘍薬物における芳香族化合物及びその用途 |
| IL300309B2 (en) * | 2020-08-12 | 2026-03-01 | Genentech Inc | Synthesis of quinazoline compounds |
| WO2022037630A1 (zh) * | 2020-08-21 | 2022-02-24 | 浙江海正药业股份有限公司 | 四环类衍生物、其制备方法及其医药上的用途 |
| CA3191279A1 (en) | 2020-08-28 | 2022-03-03 | Yi Liu | Heterocyclic compounds and uses thereof |
| US20250195521A1 (en) | 2020-09-03 | 2025-06-19 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| EP4210833A4 (en) | 2020-09-11 | 2024-09-11 | Mirati Therapeutics, Inc. | CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR |
| CA3194067A1 (en) | 2020-09-15 | 2022-03-24 | Revolution Medicines, Inc. | Ras inhibitors |
| JP2023544450A (ja) | 2020-09-23 | 2023-10-23 | エラスカ・インコーポレイテッド | 三環式ピリドン及びピリミドン |
| WO2022068921A1 (zh) * | 2020-09-30 | 2022-04-07 | 上海医药集团股份有限公司 | 一种喹唑啉类化合物及其应用 |
| TW202227441A (zh) * | 2020-10-21 | 2022-07-16 | 大陸商貝達藥業股份有限公司 | 喹唑啉化合物、包含其的藥物組合物及其應用 |
| AU2021372796A1 (en) * | 2020-10-30 | 2023-06-01 | Novartis Ag | New crystalline forms of a kras g12c inhibitor compound |
| CN120887884A (zh) * | 2020-11-06 | 2025-11-04 | 泰励生物科技(上海)有限公司 | 用于癌症治疗的KRas抑制剂 |
| CN114920738B (zh) * | 2020-11-06 | 2025-07-29 | 泰励生物科技(上海)有限公司 | 用于癌症治疗的KRas抑制剂 |
| WO2022111513A1 (zh) * | 2020-11-24 | 2022-06-02 | 杭州多域生物技术有限公司 | 一种芳香化合物、其制备方法及应用 |
| TWI880049B (zh) | 2020-12-04 | 2025-04-11 | 美商美國禮來大藥廠 | Kras g12c抑制劑 |
| JP2023553492A (ja) | 2020-12-15 | 2023-12-21 | ミラティ セラピューティクス, インコーポレイテッド | アザキナゾリン汎KRas阻害剤 |
| EP4262803A4 (en) | 2020-12-16 | 2025-03-12 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-kras inhibitors |
| WO2022127847A1 (zh) * | 2020-12-17 | 2022-06-23 | 广东东阳光药业有限公司 | 嘧啶酮衍生物及其在药物中的应用 |
| WO2022133345A1 (en) | 2020-12-18 | 2022-06-23 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| TWI795129B (zh) * | 2020-12-18 | 2023-03-01 | 大陸商正大天晴藥業集團股份有限公司 | 吡啶并嘧啶酮類化合物 |
| US20240100172A1 (en) | 2020-12-21 | 2024-03-28 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
| CN116600808B (zh) * | 2021-02-09 | 2024-10-22 | 苏州阿尔脉生物科技有限公司 | 一类作为kras突变体g12c抑制剂的四氢萘啶类衍生物、其制备方法及其应用 |
| CN117659051A (zh) * | 2021-03-30 | 2024-03-08 | 上海德琪医药科技有限公司 | Kras g12d蛋白抑制剂和其用途 |
| US20240246968A1 (en) | 2021-04-27 | 2024-07-25 | Merck Sharp & Dohme Llc | Small molecule inhibitors of kras g12c mutant |
| US20240262842A1 (en) * | 2021-04-27 | 2024-08-08 | Merck Sharp & Dohme Llc | Small molecule inhibitors of kras g12c mutant |
| US12331063B2 (en) | 2021-04-29 | 2025-06-17 | Incyte Corporation | Hetero-bicyclic inhibitors of KRAS |
| KR20240017811A (ko) | 2021-05-05 | 2024-02-08 | 레볼루션 메디슨즈, 인크. | 암의 치료를 위한 ras 억제제 |
| TW202309052A (zh) | 2021-05-05 | 2023-03-01 | 美商銳新醫藥公司 | Ras抑制劑 |
| WO2022266206A1 (en) | 2021-06-16 | 2022-12-22 | Erasca, Inc. | Kras inhibitor conjugates |
| TW202317100A (zh) | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | 包含kras g12c抑制劑的藥物組合及其用於治療癌症之用途 |
| KR20240024926A (ko) | 2021-06-24 | 2024-02-26 | 신젠타 크롭 프로텍션 아게 | 살충제로서의 2-[3-[1[(퀴나졸린-4-일)아미노]에틸]피라진-2-일]티아졸-5-카르보니트릴 유도체 및 유사한 화합물 |
| IL310291A (en) | 2021-07-23 | 2024-03-01 | Theras Inc | Compositions and methods for inhibition of ras |
| KR20240041917A (ko) | 2021-07-27 | 2024-04-01 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
| KR20240055778A (ko) | 2021-09-01 | 2024-04-29 | 노파르티스 아게 | Tead 억제제를 포함하는 제약 조합물 및 암의 치료를 위한 이의 용도 |
| US20240409558A1 (en) * | 2021-09-13 | 2024-12-12 | Biomea Fusion, Inc. | Irreversible inhibitors of kras |
| KR20240069725A (ko) * | 2021-09-22 | 2024-05-20 | 쓰추안 휘위 파머슈티컬 컴퍼니., 리미티드. | 피리딘 유도체 및 이의 용도 |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| WO2023061463A1 (zh) * | 2021-10-15 | 2023-04-20 | 广东东阳光药业有限公司 | 新的嘧啶并吡啶化合物、其药物组合物及其用途 |
| MX2024004846A (es) | 2021-10-22 | 2024-05-03 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Compuesto tetraciclico que contiene nitrogeno, metodo de preparacion del mismo y uso medico del mismo. |
| CN116102572B (zh) * | 2021-11-09 | 2025-10-10 | 中国医学科学院药物研究所 | 噻吩并嘧啶类化合物及其制备方法、用途和药物组合物 |
| CN116120243B (zh) * | 2021-11-15 | 2025-07-29 | 都创(上海)医药科技股份有限公司 | aPKC抑制剂化合物中间体片段及其制备方法和应用 |
| WO2023099608A1 (en) * | 2021-12-01 | 2023-06-08 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| WO2023099624A1 (en) | 2021-12-01 | 2023-06-08 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| US12084453B2 (en) | 2021-12-10 | 2024-09-10 | Incyte Corporation | Bicyclic amines as CDK12 inhibitors |
| CN119212994A (zh) | 2021-12-17 | 2024-12-27 | 建新公司 | 作为shp2抑制剂的吡唑并吡嗪化合物 |
| CN114507142A (zh) * | 2022-01-28 | 2022-05-17 | 上海予君生物科技发展有限公司 | 一种2-氯-4-氟-5-硝基苯甲醛的制备工艺 |
| US12071422B2 (en) * | 2022-02-07 | 2024-08-27 | Genentech, Inc. | Process for synthesis of quinazoline compounds |
| WO2023152255A1 (en) | 2022-02-10 | 2023-08-17 | Bayer Aktiengesellschaft | Fused pyrimidines as kras inhibitors |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| CN118632843A (zh) * | 2022-03-03 | 2024-09-10 | 四川汇宇制药股份有限公司 | 一种吡啶类衍生物及其用途 |
| EP4486345A1 (en) | 2022-03-04 | 2025-01-08 | Eli Lilly and Company | Method of treatment including kras g12c inhibitors and shp2 inhibitors |
| JP2025510572A (ja) | 2022-03-08 | 2025-04-15 | レボリューション メディシンズ インコーポレイテッド | 免疫不応性肺癌を治療するための方法 |
| WO2023173017A1 (en) * | 2022-03-09 | 2023-09-14 | Blossomhill Therapeutics, Inc. | Kras inhibitors for treating disease |
| AU2023231139A1 (en) | 2022-03-11 | 2024-09-05 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| EP4504710A1 (en) | 2022-04-07 | 2025-02-12 | Eli Lilly and Company | Process for making a kras g12c inhibitor |
| CA3247183A1 (en) | 2022-04-08 | 2023-10-12 | Eli Lilly And Company | TREATMENT METHOD INCLUDING KRAS G12C INHIBITORS AND AURORA A INHIBITORS |
| WO2023199180A1 (en) | 2022-04-11 | 2023-10-19 | Novartis Ag | Therapeutic uses of a krasg12c inhibitor |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| JP2025520650A (ja) | 2022-06-21 | 2025-07-03 | シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト | 殺有害生物的に活性な縮合二環式芳香族複素環式化合物 |
| US12600723B2 (en) | 2022-07-18 | 2026-04-14 | Incyte Corporation | Tetracyclic compounds as DGK inhibitors |
| US12600722B2 (en) | 2022-07-18 | 2026-04-14 | Incyte Corporation | Tetracyclic compounds as DGK inhibitors |
| US20260049089A1 (en) * | 2022-07-28 | 2026-02-19 | Shanghai Apeiron Therapeutics Company Limited | Kras inhibitor compound |
| IL318647A (en) | 2022-08-05 | 2025-03-01 | Kumquat Biosciences Inc | Heterocyclic compounds and their uses |
| GB202212641D0 (en) | 2022-08-31 | 2022-10-12 | Jazz Pharmaceuticals Ireland Ltd | Novel compounds |
| CN120659773A (zh) | 2022-11-09 | 2025-09-16 | 锐新医药公司 | 化合物、复合物以及其制备方法和用途 |
| WO2024109233A1 (zh) * | 2022-11-22 | 2024-05-30 | 四川汇宇制药股份有限公司 | 一种嘧啶并芳环化合物及其制备方法和用途 |
| WO2024110554A1 (en) | 2022-11-23 | 2024-05-30 | Syngenta Crop Protection Ag | N-[(1 -[2-[6-(pyridazin-3-yl]-1,2,4-triazol-3-yl]ethyl]-quinazolin-4-amine and n-[1-[3-(6-(pyridazin-3-yl)pyrazin-2-yl]ethyl]-8-quinazolin-4-amine derivatives as pesticides |
| EP4655298A1 (en) * | 2023-01-24 | 2025-12-03 | Theras Inc. | Compositions and methods for inhibition of ras |
| US12448399B2 (en) | 2023-01-26 | 2025-10-21 | Arvinas Operations, Inc. | Cereblon-based KRAS degrading PROTACs and uses related thereto |
| CN120882709A (zh) * | 2023-03-13 | 2025-10-31 | 四川汇宇制药股份有限公司 | 喹唑啉衍生物的盐型、晶型、其制备方法及应用 |
| WO2024201691A1 (ja) | 2023-03-28 | 2024-10-03 | 国立大学法人東北大学 | オートファジーを誘導する化合物のスクリーニング方法 |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| AR132338A1 (es) | 2023-04-07 | 2025-06-18 | Revolution Medicines Inc | Inhibidores de ras |
| CR20250420A (es) | 2023-04-07 | 2025-11-20 | Revolution Medicines Inc | Inhibidores macrocíclicos de ras |
| CN121464140A (zh) | 2023-04-14 | 2026-02-03 | 锐新医药公司 | Ras抑制剂的结晶形式、含有其的组合物及其使用方法 |
| CN121100123A (zh) | 2023-04-14 | 2025-12-09 | 锐新医药公司 | Ras抑制剂的结晶形式 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ras相關疾病或病症之組合療法 |
| EP4721766A1 (en) | 2023-06-02 | 2026-04-08 | Daiichi Sankyo Company, Limited | Combination of (anti-her3 antibody)-drug conjugate and rasg12c inhibitor |
| CN121605110A (zh) | 2023-06-06 | 2026-03-03 | 金橘生物科技公司 | 取代杂环化合物及其用途 |
| AU2024290917A1 (en) * | 2023-07-03 | 2026-01-22 | Cervero Therapeutics, LLC | Polo-like kinase 1 inhibitors |
| WO2025016899A1 (en) | 2023-07-19 | 2025-01-23 | Bayer Aktiengesellschaft | Spirocyclic compounds for the treatment of cancer |
| WO2025022008A1 (en) | 2023-07-27 | 2025-01-30 | Syngenta Crop Protection Ag | Pesticidally active quinazoline compounds |
| WO2025022007A1 (en) | 2023-07-27 | 2025-01-30 | Syngenta Crop Protection Ag | Pesticidally active quinazoline compounds |
| WO2025026903A1 (en) | 2023-07-31 | 2025-02-06 | Bayer Aktiengesellschaft | Imidazo pyrimidine compounds for the treatment of cancer |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024359243A1 (en) * | 2023-10-09 | 2026-04-23 | Incyte Corporation | Processes for preparing kras inhibitors |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| AU2024361909A1 (en) | 2023-10-20 | 2026-03-26 | Merck Sharp & Dohme Llc | Small molecule inhibitors of kras proteins |
| WO2025132349A1 (en) | 2023-12-19 | 2025-06-26 | Syngenta Crop Protection Ag | Pesticidally active quinazoline compounds |
| WO2025132754A1 (en) | 2023-12-21 | 2025-06-26 | Syngenta Crop Protection Ag | Pesticidally active quinazoline compounds |
| PY24113579A (es) | 2023-12-21 | 2025-07-30 | Syngenta Crop Protection Ag | Compuestos de quinazolina con actividad plaguicida |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217247A1 (en) * | 2024-04-10 | 2025-10-16 | Amgen Inc. | Tethered spiro-heterocyclic inhibitors of kras g12c mutant proteins and uses thereof |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ras抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026035945A1 (en) | 2024-08-07 | 2026-02-12 | Tesseract Medicines Us, Llc | Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload |
| WO2026035947A1 (en) | 2024-08-07 | 2026-02-12 | Tesseract Medicines Us, Llc | Kras-targeting covalent-induced drug conjugates comprising a topoisomerase payload |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026064527A1 (en) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload |
| WO2026064520A1 (en) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| CN121064192A (zh) * | 2025-08-21 | 2025-12-05 | 广州国家实验室 | 一种kras泛抑制剂及其制备方法与应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US510A (en) | 1837-12-07 | soeel | ||
| US5863A (en) | 1848-10-17 | Matthias p | ||
| US5861A (en) | 1848-10-17 | Locking umbrella and parasol | ||
| US949A (en) | 1838-09-27 | Improvement in roller cotton-gins for ginning long-staple and other kinds of cotton | ||
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| ES2153031T4 (es) | 1995-04-20 | 2001-05-16 | Pfizer | Derivados del acido arilsulfonil hidroxamico como inhibidores de mmp y tnf. |
| ATE225343T1 (de) | 1995-12-20 | 2002-10-15 | Hoffmann La Roche | Matrix-metalloprotease inhibitoren |
| JP3195756B2 (ja) | 1996-07-04 | 2001-08-06 | 公子 吉水 | 潤滑補助体 |
| KR20000067904A (ko) | 1996-07-18 | 2000-11-25 | 디. 제이. 우드, 스피겔 알렌 제이 | 매트릭스 메탈로프로테아제의 포스피네이트계 억제제 |
| KR20000068248A (ko) | 1996-08-23 | 2000-11-25 | 디. 제이. 우드, 스피겔 알렌 제이 | 아릴설포닐아미노 하이드록삼산 유도체 |
| JP3338064B2 (ja) | 1997-01-06 | 2002-10-28 | ファイザー・インク | 環状スルホン誘導体 |
| NZ336840A (en) | 1997-02-03 | 2001-01-26 | Pfizer Prod Inc | Arylsulfonylamino hydroxamic acid derivatives useful in the treatment of tumor necrosis factor and matrix metalloproteinase mediated diseases |
| JP2000507975A (ja) | 1997-02-07 | 2000-06-27 | ファイザー・インク | N−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用 |
| EP0960098A1 (en) | 1997-02-11 | 1999-12-01 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives |
| GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
| GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
| PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
| PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
| US6890747B2 (en) * | 2000-10-23 | 2005-05-10 | Warner-Lambert Company | Phosphoinositide 3-kinases |
| US7074801B1 (en) * | 2001-04-26 | 2006-07-11 | Eisai Co., Ltd. | Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof |
| WO2008009078A2 (en) * | 2006-07-20 | 2008-01-24 | Gilead Sciences, Inc. | 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections |
| JP2013516422A (ja) * | 2009-12-30 | 2013-05-13 | アビラ セラピューティクス, インコーポレイテッド | タンパク質のリガンド−指向性共有的修飾 |
| BR112012022868A2 (pt) * | 2010-03-16 | 2018-06-05 | Merck Patent Gmbh | morfolinilquinazolinas |
| JP2013107855A (ja) * | 2011-11-22 | 2013-06-06 | Mitsubishi Tanabe Pharma Corp | 医薬組成物 |
| EP2836482B1 (en) * | 2012-04-10 | 2019-12-25 | The Regents of The University of California | Compositions and methods for treating cancer |
-
2014
- 2014-10-10 EP EP14799915.5A patent/EP3055290B1/en active Active
- 2014-10-10 AU AU2014331794A patent/AU2014331794C1/en active Active
- 2014-10-10 MX MX2016004360A patent/MX380928B/es unknown
- 2014-10-10 WO PCT/US2014/060036 patent/WO2015054572A1/en not_active Ceased
- 2014-10-10 UA UAA201605067A patent/UA119971C2/uk unknown
- 2014-10-10 BR BR112016008016A patent/BR112016008016B8/pt active IP Right Grant
- 2014-10-10 EP EP19195037.7A patent/EP3636639A1/en active Pending
- 2014-10-10 SG SG11201602662YA patent/SG11201602662YA/en unknown
- 2014-10-10 CN CN201480055783.1A patent/CN106488910B/zh active Active
- 2014-10-10 EA EA201690752A patent/EA033689B9/ru active IP Right Revival
- 2014-10-10 CA CA2926328A patent/CA2926328C/en active Active
- 2014-10-10 JP JP2016521333A patent/JP6559123B2/ja active Active
- 2014-10-10 KR KR1020167011577A patent/KR20160076519A/ko not_active Ceased
-
2016
- 2016-03-21 IL IL244699A patent/IL244699B/en active IP Right Grant
- 2016-03-21 PH PH12016500538A patent/PH12016500538B1/en unknown
- 2016-04-05 ZA ZA2016/02245A patent/ZA201602245B/en unknown
- 2016-04-08 NI NI201600049A patent/NI201600049A/es unknown
- 2016-04-19 NO NO20160646A patent/NO20160646A1/en not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016532656A5 (https=) | ||
| US7435823B2 (en) | Compounds and methods of use | |
| AU2005312048B2 (en) | Quinolines and quinazoline analogs and their use as medicaments for treating cancer | |
| CA2605680C (en) | Substituted amide derivatives as protein kinase inhibitors | |
| CN1133625C (zh) | 喹唑啉衍生物 | |
| US9855269B2 (en) | Aminoquinazoline and pyridopyrimidine derivatives | |
| JP2008521900A5 (https=) | ||
| CN1320121A (zh) | 作为蛋白质酪氨酸激酶抑制剂的取代的3-氰基喹啉 | |
| EP2292615A1 (en) | Quinazoline compounds | |
| AU2007338792A1 (en) | Substituted heterocycles and methods of use | |
| AU2003202094A1 (en) | Quinazoline compounds | |
| JP2014531465A5 (https=) | ||
| JP2020526547A5 (https=) | ||
| JP2020512401A5 (https=) | ||
| MXPA06008327A (en) | Compounds and methods of use | |
| HK1154586A (en) | Quinazoline compounds |